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ABSTRACT OF DISSERTATION

IDENTIFICATION OF SUMOYLATED PROTEINS AND INVESTIGATION OF
PROTEIN UBIQUITINATION IN THE NF-κB PATHWAY
SUMOylation and ubiquitination are important post-translational modifications.
While ubiquitination is well known for targeting proteins for degradation, SUMOylation
often regulates the intracellular localization of substrates. In the first project of this
dissertation, we developed proteomic strategies to identify novel SUMOylated proteins in
mammalian cells. In the second project, we investigated the regulation of protein
ubiquitination in the NF-κB signaling pathway in the context of Paget’s disease of bone
(PDB).
Identification of SUMOylated proteins has been a challenge because of low
abundance of SUMOylation substrates. Here, we utilized a mass spectrometry (MS)based proteomic approach to identify novel SUMOylated proteins in mammalian cells.
Seventy-four unique proteins were commonly identified in the collection of four SUMO1 plasmids, thus considered candidate SUMOylated proteins. Many of these proteins are
associated with the nucleus. The results were validated by confirming SUMOylation of a
novel substrate Drebrin and a well known substrate Ran-GAP1. Furthermore, the
potential SUMOylation sites in Drebrin have been identified and confirmed using sitedirected mutagenesis.
PDB is a disorder characterized by increased bone turnover containing
hyperactive osteoclasts. Mutations in Sequestosome 1 (p62) are associated with 40% of
familial PDB. P62 is a scaffold protein and plays a critical role in regulating
ubiquitination of TRAF family signaling molecules and mediating the activation of NFκB by RANK and TNFα ligands. P62 also plays a critical role in shuttling substrates for
autophagic degradation. The objective of this project is to determine the effects of PDBassociated p62 mutants on NF-κB signaling and autophagy. We compared the effect of
wild-type (WT) p62 and PDB mutations (A381V, M404V and P392L) on the TNFαinduced NF-κB signaling using an NF-κB luciferase assay. Our results show that these
p62 mutations increased the NF-κB signaling. In addition, we found that the PDB
mutations did not change the interaction between p62 and the autophagy marker protein
LC3. In summary, the PDB mutations in p62 are likely gain-of-function mutations that

can increase NF-κB signaling and potentially contribute to disease progression. Based on
the results, we proposed a model to speculate the synergetic role of p62 PDB mutant on
NF-κB signaling and autophagy.
KEYWORDS: SUMOylation; ubiquitination; Paget’s disease of bone (PDB); p62; NFκB signaling
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Chapter 1. Background and introduction

Dissertation overview

SUMOylation

and

ubiquitination

are

two

important

post-translational

modifications [1, 2]. This dissertation consists of two parts. In the first part (Chapter 2),
we developed a relatively simple proteomic method to identify SUMOylated proteins in
mammalian cells. We are also the first group to identify and validate that an actin-binding
protein, Drebrin [3], could be SUMOylated. The second part (Chapter 3 and 4) of this
dissertation is related to “ubiquitination” for the following reasons. Firstly, p62 is an
ubiquitin-binding protein [4-6]. Secondly, most of the PDB-associated p62 mutations are
in the ubiquitin-associated (UBA) domain [7]. Thirdly, in Chapter 3, we proposed that
p62 PDB mutants increase the NF-κB signaling through increasing TRAF6
polyubiquitination. Fourthly, in Chapter 4, we studied the effect of p62 PDB mutants in
autophagy. Autophagy is involved in degradation of polyubiquitinated proteins [8].
Currently, little is known about cellular consequences of PDB-associated p62
mutants currently [9]. To fill in this gap, we focused on studying the cellular
consequences of PDB-associated p62 mutants on the NF-κB signaling and autophagy.
We found that p62 PDB mutants increased TNFα-induced NF-κB signaling, but not
through TRAF6 polyubiquitination (Chapter 3). Additionally, we showed that PDB
mutants did not change the interaction between p62 and the autophagy marker protein
LC3 (Chapter 4). Finally, an integrated model for the role of PDB mutant p62 in NF-κB
signaling and autophagy is proposed (Fig. 5.1).

1

SUMOylation

Discovery of SUMO
The small ubiquitin-like protein modifier (SUMO) was firstly discovered as
reversible post-translational modification by several groups in the middle 1990s [10-12].
The first SUMOylated protein identified is Ran-GTPase-activating protein 1 (Ran-GAP1),
which had been implicated in both nuclear transport and the control of mitosis [11, 12].
In 1997, the researchers found that cells contain two forms of RanGAP1, 70 kDa and 90
kDa [11]. Further analysis showed that the larger form contained a 97 amino acid protein,
which is similar to ubiquitin in its shape, known as SUMO [12, 13].
Generally, three major SUMO paralogues, SUMO-1, SUMO-2 and SUMO-3 are
expressed in cells [14]. It is not certain whether SUMO-4 protein is expressed in cells
although a gene encoding SUMO-4 has been reported [15]. SUMO-2 and SUMO-3 are
often referred to as SUMO-2/3 because they share 98% sequence similarity. However,
SUMO-2/3 and SUMO-1 have only approximately 50% sequence identity [10, 16].
Human small ubiquitin-like modifier 1 (hSUMO-1) is a protein of 101 amino acids,
similar to ubiquitin in 3D structure, even though they only share 17% homology at the
amino acid level [17-19]. The SUMO-1 precursor has to be cleaved by SUMO-specific
proteases to expose a C-terminal glycine-glycine (GG) functional group for subsequent
SUMO activation and conjugation [1].
SUMOylation often regulates protein intracellular localization, protein-protein
interactions or transcription regulator activity [2, 20]. SUMOylation is essential to normal
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cellular behavior. Dysregulation of protein SUMOylation has been associated with a
number of diseases such as cancer, neurodegenerative disease, viral infection, diabetes
and developmental defects [2].
SUMOylation vs. ubiquitination
SUMOylation

and

ubiquitination

are

two

important

post-translational

modifications in the cells. They share many similarities but they are also different in
many aspects [21].
(1) Similarity
SUMO and ubiquitin have similar protein size, tertiary structure and a C-terminal
di-glycine motif. Both SUMO and ubiquitin target the protein with the help of E1
(activating enzyme), E2 (conjugating enzyme) and E3 ligases. In addition, both SUMO
and ubiquitin proteins are synthesized as immature precursors. These precursors are
processed by the specific hydrolase for subsequent activation and conjugation [14, 22].
(2) Difference
Ubiquitination is well known for targeting substrates for degradation, whereas
SUMOylation regulates a substrate’s functions mainly by altering the intracellular
localization, protein-protein interaction and transcription factor activity. In addition, the
ubiquitin pathway has a large number of E2 s and E3 s, whereas the SUMO pathway only
uses a single E2 and a few E3 s [17].

SUMO conjugation, deSUMOylation and SUMO consensus sequence
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It is well known that ubiquitin conjugation requires E1 ubiquitin-activating
enzyme, E2 ubiquitin-conjugating enzyme and E3 ubiquitin ligase [23]. SUMO
conjugation is very similar to ubiquitin conjugation (Fig. 1.1). SUMO proteins are
synthesized as inactive precursors, which must first undergo a C-terminal cleavage
mediated by a family of sentrin/SUMO-specific protease (SENP) enzymes. This cleavage
exposes a di-glycine motif, which is available for subsequent activation and conjugation
[14]. In each conjugation cycle, SUMO is activated in an ATP-dependent manner by the
E1 “activating” enzyme. SUMO is then passed to the active site of the conjugating
enzyme Ubc9 (ubiquitin-conjugating 9). Finally, SUMO is covalently attached to lysine
residues of the target protein through the isopeptide bond between the terminal glycine
residue and the ε-amino group of a lysine residue in the target protein by SUMO E3
ligase [1, 24, 25]. SUMOylation is a highly dynamic process that can be reversed by
deconjugating enzymes such as the SENP enzymes [26]
The SUMO-1 consensus sequence is a motif of conserved residues next to the
modified lysine residue and is found in many identified SUMO-1 substrates [27]. The
sequence is ΨKXE/D, where Ψ is a large hydrophobic residue (such as Val, Ile, Leu, Met,
or Phe). K is the lysine to which SUMO-1 is conjugated and X is any amino acid, D is
aspartic acid and E is glutamic acid. More than two-thirds of the known substrate proteins
have at least one SUMOylation consensus sequence ΨKXE/D [2, 28]. However,
SUMOylation can also occur at lysine residues without this consensus motif, such as nonconsensus SUMOylation sites. In addition, although not all lysine residues within the
ΨKXE/D motif are SUMOylated [1], SUMOylation consensus sequence ΨKXE/D is still
generally believed to be helpful for predicting SUMOylation sites.
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Classification of SUMOylation substrates
To date, more than 120 mammalian substrate proteins for SUMOylation have
been identified [2]. Based on the subcellular localization of identified SUMOylation
substrates, they could be classified as nuclear proteins, cytoplasmic proteins and transmembrane proteins. The majority of these substrates are nuclear proteins, indicating that
SUMOylation is primarily involved in nuclear functions. However, a growing number of
non-nuclear proteins have been identified, suggesting important non-nuclear roles of
SUMOylation [29-31].
The nuclear SUMOylation substrates are well studied. These substrates could be
further classified into nuclear pore complexes, transcription factors and coregulators,
DNA replication and repair proteins, as well as kinetochore and centromere proteins [2,
32-34]. Functions of SUMOylation of these nuclear proteins are summarized in the Fig.
1.2.
A growing number of non-nuclear SUMOylation substrates have been identified,
indicating more functions of SUMOylation beyond those related to the nucleus [2]. RanGAP1, the first identified SUMOylation substrate is a cytoplasmic protein. SUMOylation
is clearly required for targeting Ran-GAP1 to the nuclear pore complex (NPC) [11]. Also,
some identified SUMOylation substrates are transmembrane proteins, such as death
receptors, Fas and TNFR1. SUMOylation of these receptors inhibits their apoptotic
signaling [2, 35]. It is noted that a number of non-nuclear SUMOylation substrates are
involved in signal transduction. SUMOylation of these proteins could change the activity,
stability, or subcellular distribution of the proteins and eventually alter signaling events.
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For example, SUMOylation protects inhibitor of NF-κB (IκB) from ubiquitination and
degradation by 26S proteasome [2, 30].

Functional consequences of SUMOylation
The major functional consequences of SUMOylation include alteration of protein
localization, protein-protein interactions and transcription regulator activity [2, 36].
(1) Protein localization
As mentioned earlier, Ran-GAP1 is a cytosolic protein. Only SUMOylated RanGAP1 binds Ran-GTP binding protein (RanBP2), which mediates SUMOylated RanGAP1 translocation from the cytosol to the nuclear pore [11, 37]. Therefore,
SUMOylation is critical for nuclear import of some proteins. In addition, SUMOylation
could also target substrate proteins to specific locations within the cytoplasm. For
example, DRP1 is a GTPase protein required for mitochondrial fission. SUMOylation of
DRP1 facilitates its recruitment from the cytosol to the mitochondrial outer membrane
[38].
(2) Protein-protein interactions
SUMOylation of Ran-GAP1 is also an example of SUMOylation being involved
in protein-protein interactions. As discussed earlier, only SUMOylated Ran-GAP1 can
bind RanBP2. It is hypothesized that SUMO may serve as an interaction “hub” that
recruits new interacting proteins to the substrate [1, 2]. For another example, it has been
demonstrated that SUMOylation of transcription factor Elk1 could recruit the histone
deacetylase 2 (HDAC2). This recruitment has been shown to result in decreased histone
acetylation of Elk-1-regulated promoters and thus transcriptional repression of Elk-1
target genes [39].
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(3) Transcription regulator activity
Most SUMOylation substrates are nuclear proteins. Particularly, the primary
nuclear SUMOylation substrates are transcription factors and regulators. In most cases,
SUMOylation negatively regulates gene expression by either enhancing the function of
transcription repressors or inhibiting the function of transcription activators [34, 40, 41].
However, the opposite occurs occasionally. For example, heat shock factor 1 (HSF1) is
SUMOylated in response to stress and HSF1 SUMOylation often leads to activation of its
target genes [13, 42].

SUMOylation and disease
As described above, SUMOylation is a dynamic process that could be reversed by
deconjugating enzymes such as the SENP enzymes [1, 26]. A delicate balance between
SUMOylation and deSUMOylation is essential to normal cell functions (Fig. 1.2).
Growing evidence has shown that the loss of this balance in SUMOylation and
deSUMOylation can lead to diseases including cancer, diabetes and neurodegenerative
diseases such as Alzeimer’s disease, Parkinson’s disease, familial amyotrophic sclerosis
(fALS) and Huntington’s disease [2, 14, 43]. For example, a recent study has shown that
SUMOylation of amyloid precursor protein (APP) close to the β-secretase cleavage site is
associated with a decrease of Aβ aggregates, which is generally believed a probable cause
of Alzeimer’s disease [14, 29, 31]. The causative relationships between the deregulation
of SUMOylation and pathogeneses of the diseases are still unclear and under active
investigation. Studies so far have suggested that SUMO target proteins might be
therapeutic targets for treating these diseases [14, 43].
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In our study, we used a modified proteomic method to identify SUMOylated
proteins in HEK293 cells. We also found that Drebrin is a novel substrate for
SUMOylation. Background about Drebrin is described as below.

Discovery, isoforms and domains of Drebrin
Developmentally-regulated brain protein (Drebrin) is an actin-binding protein,
involved in the regulation of actin filament organization. Drebrin plays an important role
during the formation of neurites and cell protrusions of motile cells [44]. The expression
level of Drebrin is very high in the cerebral cortex, hippocampus, thalamus and striatum
[45]. Drebrin was originally discovered by Shirao et al. [46].
Drebrin has three isoforms including E1, E2 (embryonic) and A (adult) isoform,
which are generated by alternative RNA splicing from a single Drebrin gene [47].
Drebrin E1 and E2 were first identified as developmentally regulated brain proteins by
two-dimensional gel electrophoresis in 1985 [46]. Drebrin A was discovered using a
monoclonal antibody against Drebrin E in 1986 [48]. A cDNA clone for a common
domain of Drebrin E1, E2 and A was first isolated from brains of 10-day chick embryos
in 1988 [3, 49]. All three isoforms are strongly expressed in neurons [44]. On SDSPAGE gels, the molecular weight of Drebrin A is about 125 kDa and the molecular
weight of Drebrin E is about 115 kDa [45].
The N-terminal domain of Drebrin is an actin-depolymerizing factor homology
(ADF-H) domain which is highly conserved across vertebrate [50]. Also, there is an
actin-binding domain close to ADF-H. In the C terminus of Drebrin, there are homer8

binding motifs [44]. Homer proteins are scaffold proteins at the post-synaptic density
where they facilitate synaptic signaling and appear to be critical in learning and memory
[51].

Drebrin contributes to the formation of filopodia
The formation and maintenance of an appropriate shape is fundamental to cells. It
is also important for cells to modulate morphology in response to changing
environmental stimuli. The cytoskeleton plays an important role to provide both a rigid
scaffold and mechanical forces to move the cell [44]. Also, the cytoskeleton is regulated
by many proteins which bind cytoskeletal components such as microtubules and actin
filaments. Drebrin is one of these actin-binding protein [44], and growing evidence shows
that Drebrin is important for controlling cell shape and function by its interaction with
other proteins [44].
The most visualized function of Drebrin is that Drebrin contributes to filopodia
formation in neurons and other cell types [52]. In 1992, it was firstly reported that
exogenous GFP-Drebrin A accumulated within spines and elongated the length of spine
[53-55]. Later, it was reported that overexpression of full length Drebrin, or truncations
containing the actin-binding domain, induced the formation of numerous microspikes in
fibroblasts and massive spines in cultured hippocampal neurons [44, 56, 57]. Also, it was
shown that overexpression of Drebrin E2 in cultured epithelial cells resulted in a
phenotype similar to that produced in neurons and fibroblasts [44, 58]. It was also shown
that filopodia formation could also be inhibited by a reduced amount of Drebrin [52].
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In our study, we used the proteomic method to first show that Drebrin could be
SUMOylated. Additionally, we found the potential SUMOylation sites of Drebrin. We
also try to investigate the functional consequence of Drebrin SUMOylation.
Next, we will talk about another post-translational modification, ubiquitination,
which is similar with SUMOylation described above. Here, we firstly will introduce a
disease called Paget’s disease of bone (PDB) because mutation in the gene encoding an
ubiquitin-binding protein, p62 is associated with PDB. Then, we will describe the protein
p62 in detail. We also will introduce NF-κB signaling, in which ubiquitination of many
proteins occur. In the end, we will describe autophagy, which is involved in degradation
of polyubiquitinated proteins [8].
Paget’s disease of bone (PDB)

Prevalence and symptoms of PDB
Paget’s disease of bone is named after Sir James Paget who was a British Surgeon.
In 1876, he published a scientific article describing cases of previously unrecognized
chronic bone disease, which he called “osteitis deformans”. Over 120 years after Sir
Paget’s finding, scientists and clinicians began to make significant progress in
understanding the etiology of the condition we now know as Paget’s disease of bone
(PDB) [59], which is the second most common bone disease after osteoporosis [60].
PDB is most common in England, Western Europe, and North America. Very few
cases have been reported in Asia and Africa [59]. Approximately 3% of individuals aged
over 50 years are affected with PDB in Caucasian populations [7, 61]. PDB is not lethal,
but a chronic disorder that typically results in deformed bones [9]. The symptoms include
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bone pain, susceptibility to pathological fractures, osteoarthritis, headache, deafness and
neurological complications [59, 62, 63]. Osteosarcoma often occurs in PDB patients [64].
An elevated level of alkaline phosphatase, bone scans, x-rays help the diagnosis [61].
Currently, the common drug for treating the PDB are bisphosphonates, a class of
relatively non-selective compounds that target and induce apoptosis of osteoclasts [7].

PDB is a disorder of bone remodeling

Bone mass in human being is controlled by both osteoclasts (bone-resorbing cells)
and osteoblasts (bone-forming cells) [65]. The opposing activities of these two cell types
ensure that bone is constantly remodeled in a process essential to maintain adult bone
structure and function [59].
PDB is characterized by focal areas of increased bone turnover containing
enlarged hyperactive osteoclasts [7, 66]. Pagetic lesions contain increased numbers of
osteoclasts compared with normal bone, which have increased size and contain more
nuclei than normal osteoclasts [7]. The increased osteoclast activity leads subsequently to
increases in osteoblast activity [59]. Although bone resorption (osteoclast) initially
exceeds formation (osteoblast), bone formation greatly exceeds bone resorption in later
stages. Therefore, the overall process of bone formation becomes accelerated and
disorganized, ultimately resulting in abnormal bone structure.

RANK plays an important role in the formation of osteoclast
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Receptor activator of nuclear factor kappa-B ligand (RANKL), also known as
TNF-related activation-induced cytokine (TRANCE) or osteoprotegerin ligand (OPGL),
is a member of the tumor necrosis factor superfamily. It is most abundantly expressed as
a cell surface protein by bone marrow stromal cells [67-69]. In 1998, RANKL (OPGL)
was shown to be the main osteoclastogenic cytokine both in vitro and in vivo [67, 70, 71].
Osteoclast precursors are monocyte/macrophages. It was reported that RANKL
could transform the macrophages to osteoclasts [67, 70, 71]. RANKL could interact with
its receptor RANK (Fig. 1.5) [72]. RANKL and RANK are encoded by Tnfsf11 and
Tnfrsf11a genes, respectively [67]. It has been reported that both Tnfsf11-knockout mice
(without RANKL) and mice in which Tnfrsf11a has been deleted (RANK–/–) fail to
generate osteoclasts [67, 71, 73]. However, Tnfrsf11a knockout mice (RANK –/–) could
be rescued by RANK-expressing haematopoietic cells, which suggests that RANK plays
an important role in osteoclast formation [67, 73].

Etiology of PDB: disordered RANKL-induced NF-κB signaling
It has been generally accepted that disordered osteoclast RANKL-induced NF-κB
signaling may be central to disease etiology [9]. RANKL-induced NF-κB signaling plays
a role in regulating the transformation of osteoclast to activated osteoclast [67].
Therefore, hyperactivated osteoclasts identified in PDB patient might be due to the upregulation of RANKL-induced NF-κB signaling [9].
There are other factors that also contribute to PDB. It is suggested that PDB
etiology is also involved with slow virus [59]. It has been shown that the infection of
osteoclasts with a paramyxovirus is a possible cause of PDB [74]. Exposure to
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environmental toxin could be another factor affecting PDB incidence. PDB cases in
Lancashire (county of historic origin in the North West of England) identified in a 1974
survey have been linked to the cotton industry. It was proposed that arsenic pesticide
from cotton bales might be responsible for the high prevalence of disease [75].
Both viral infection and exposure to environmental toxins such as arsenic may
upregulate the expression of SQSTM1 (p62), which is an important protein in RANKLinduced NF-κB signaling pathway [7, 9, 59].

Genetics of PDB: p62 (SQSTM1) mutations
The most common genetic mutations found in classical PDB patients are in the
SQSTM1 (sequestosome1) gene, located on chromosome 5 at the PDB3 locus [59, 76].
This gene encodes the SQSTM1 protein (also known as p62), which has diverse
functional properties [59, 76]. In osteoclasts, p62 appears to be an important component
in the RANKL-induced NF-κB signaling pathway [59, 77]. Mutations in p62 gene are a
major cause of PDB, but do not account for all cases of PDB [7]. Mutations in p62 gene
have also been associated with familial and sporadic disease in up to 40% of cases [7].
To date, over 20 PDB-associated p62 mutations have been identified. Most of the
p62 PDB mutations are either missense or truncating mutations in the ubiquitinassociated (UBA) domain, the C terminus of the p62 protein. A few p62 PDB mutations
are outside of UBA domain [9].
Recent studies have supported the idea that p62 PDB mutations including P392L,
P384S and K378X, are associated with increased RANKL-induced NF-κB signaling
compared with wild-type p62 [9, 78-81]. While p62 mutations are linked to most cases of
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PDB, mutations in genes encoding other proteins including VCP and RANK, are linked
to PDB- related syndromes [59].
In our study, we are interested in cellular consequences of PDB-associated p62
mutations. Thus, we investigated the impact of these p62 mutations on NF-κB signaling
and autophagy.

P62 (Sequestosome 1)

The domain structures of p62
P62 is also called sequestosome 1 or SQSTM1 [82]. It is a conserved
multifunctional protein that is mainly involved in cellular signaling, protein degradation,
protein aggregation and apoptosis [5, 83-85]. Plus, p62 is a cellular protein which is
found in almost all mammalian cell types [86]. It was identified as a common component
of cytoplasmic inclusions in protein aggregation diseases including amyotrophic lateral
sclerosis (ALS) [87] and other neurodegenerative diseases [88].
The p62 gene has 8 exons and encodes a protein of 440 amino acids [89]. The
diverse functions of p62 could be reflected by its domain structure (Fig. 1.4 A) [90].
Generally, p62 consists of six domains/motifs: Phox and Bem1 (PB1) domain, ZZ-type
zinc finger, the SOD1 mutant interaction region (SMIR), TRAF6 binding (TB) motif, the
microtubule-associated protein 1 light chain 3B (LC3) interaction region (LIR) and an
ubiquitin binding-associated (UBA) domain [5, 83].
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(1) PB1 domain
The N-terminal Phox and Bem1 (PB1) domains of p62 could form heterodimers
with other PB1 domains, and could also form homodimers and homooligomers of p62
[83, 91, 92]. The PB1 domain of p62 interacts with the PB1 domain of a number of
proteins including atypical protein kinase C (aPKC), MAPK/ERK kinase 5 (MEK5),
extracellular responsive kinase (ERK) and neighbor of BRCA1 gene 1 (NBR1).
Particularly, the interaction of p62 and aPKC plays an important role in NF-κB signaling
described below [5].
(2) ZZ-type zinc finger
The ZZ-type zinc finger mediates the interaction of p62 with receptor-interacting
protein kinase 1 (also called RIP, RIP1 or RIPK1) [83, 93]. This interaction also plays an
important role in the TNFα-induced NF-κB signaling pathway.
(3)SMIR motif
We identified a motif that is essential for the interaction of p62 with mutants of
the Cu/Zn superoxide dismutase (SOD1) linked to familial ALS [83]. The SOD1 mutant
interaction region (SMIR, residues 178-224) is the actual sequence that interacts with
mutant SOD1. In particular, the conserved W184, H190 and the positively charged R183,
R186, K187 and K189 residues within the SMIR are critical for the interaction because
substitution of these residues with alanine significantly impaired the p62-mutant SOD1
interaction. In addition, oligomerization of p62 via the PB1 domain also plays an
indispensable role in the p62-mutant SOD1 interaction [83]. The ubiquitin-independent
recognition of misfolded proteins by SMIR is illustrated in Figure 2.
(4) TB motif
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P62 binds to the TNF receptor-associated factor 6 (TRAF6) through the TRAF6
binding (TB) motif. TRAF6 is an E3 ubiquitin ligase in the RANKL-induced NF-κB
signaling pathway. The interaction of p62 with TRAF6 could promote K63 linked
polyubiquitination of TRAF6, which could further activate NF-κB [5]. The interaction of
p62 with the E3 ubiquitin ligase TRAF6 promotes K63-linked polyubiquitination of
TRAF6 and of other substrates such as Trk A and IKKγ [94-96].
(5) LC3 interaction region (LIR)
The microtubule-associated protein 1 light chain 3B (LC3) is a protein essential to
autophagosome formation [83, 97]. The LC3 interaction region (LIR) of p62 can directly
interact with LC3 [83, 97]. Particularly, one PDB-associated p62 mutation, D335E, is
found in this LIR region [98].
(6) Ubiquitin binding-associated (UBA) domain
The C-terminus of ubiquitin binding-associated (UBA) domain of p62 is
responsible for ubiquitin binding [82, 99, 100]. It is proposed that p62 interacts with
polyubiquitinated proteins through the UBA domain. Once the polyubiquitin chain of a
substrate protein binds to the UBA domain of p62, the substrate can be either translocated
to the proteasome or autophagosome for degradation (see below).
The role of p62 in protein degradation
P62 plays a critical role in both ubiquitin-proteasome system (UPS) and
autophagy, the two major known protein degradation pathways in mammalian cells (Fig.
1.6). P62 was reported to be a shuttling factor to the proteasome [4, 82, 101].
Accumulating evidence suggests that the involvement of p62 in autophagy is likely more
important. Moreover, p62 can mediate the cross-talk between the UPS and autophagy. It
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was proposed that p62 accumulation after autophagy inhibition could further suppress the
clearance of ubiquitinated proteins destined for proteasomal degradation [102].
The p62 protein plays a critical role in autophagy as a cargo receptor. P62 is
frequently detected in protein inclusions related to human diseases [88, 103-105]. The
depletion of p62 inhibited autophagic degradation of aggregation-prone polyglutamineexpanded huntingtin inclusions while p62 protected cells from cell death induced by
polyglutamine-expanded huntingtin [89]. Inhibition of autophagy caused elevated levels
of p62 and induced more and larger p62 inclusions [89, 106, 107]. It was found that p62
actually regulates the formation and autophagic removal of protein inclusions [89, 106].
p62 binds directly to LC3 through its “LC3 interaction region” (LIR) [89, 97] that is
critical to its ability to shuttle substrates to autophagosomes for degradation [97, 108,
109]. The C-terminal UBA domain can interact with polyubiquitin chains [100]. It was
proposed that p62 targets ubiquitinated protein aggregates to autophagy through an
interaction between its UBA domain and polyubiquitin [97]. However, our lab found that
the UBA domain of p62 was dispensable for the recognition of familial ALS-related
mutant SOD1 [83]. Instead, an internal sequence motif, the SMIR plays a critical role in
mutant SOD1 recognition, suggesting that p62 might also target protein cargos for
autophagic degradation via ubiquitin-independent mechanisms [83].

PDB-associated p62 mutations and phenotype
The most common genetic mutations found in classical PDB patients are in the
p62 gene, located on chromosome 5 at the PDB3 locus [59, 76]. To date, over 20 PDB-
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associated p62 mutations have been identified [9]. Most of the p62 PDB mutations are in
the UBA domain [110]. A few p62 PDB mutations are outside of UBA domain [9].

(1) p62 UBA domain mutations
In 2003, the three-dimensional structure of the p62 UBA domain (residues 387436) was determined by protein NMR (Fig. 1.4 B) [99, 111]. Identified p62 UBA domain
mutations include P387L [112], P392L [113, 114], L394X [115], E396X [112], S399P
[116], M404V [115, 117], G411S [115], G425R [115, 117], M404T [116] and others.
Moreover, it was demonstrated that all of these mutations impaired K48-linked
polyubiquitin binding by p62 in vitro [116]. Therefore, it was proposed that the disease
mechanism in PDB involves a common loss of ubiquitin binding of p62. Interestingly,
the mutations found in the UBA domain, P392L, G411S and G425R were also recently
reported in ALS patients [118]. These findings suggest that p62 mutations might
represent a causative or risk factor in ALS too.

(2) p62 non-UBA domain mutations
In recent years, more PDB-associated p62 mutations have been found in the nonUBA domain. A D335E missense mutation located in the LC3-intearcting region (LIR)
of p62, 50 amino acids away from UBA domain was identified [9]. Other non-UBA
mutations include P364S [79], A381V [78, 98], Y383X [98] and others.
In our study, we mainly investigated the effect of PDB-associated p62 mutations
on NF-κB signaling and possible mechanisms. We selected three p62 UBA domain
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mutations (P392L, M404V and G411S) and two p62 non-UBA domain mutations
(D335E and A381V) in our work.

NF-κB signaling
Nuclear factor κB (NF-κB) is a transcription factor found in almost all
mammalian cell types [119, 120]. NF-κB is well known for regulation of immune
responses and inflammation [119, 121]. Growing studies have shown that NF-κB is also
involved in the oncogenesis [121], bone diseases [65] and cell death [122].
Currently, the numerous studies of NF-κB consist of website (www.nf-kb.org),
patent and around 25,000 publications [120]. Here, we only focus on introducing
RANKL-induced and TNFα-induced NF-κB signaling pathways which are related to our
research topic.
RANKL-induced NF-κB signaling
RANKL is a cytokine that is highly expressed in bone marrow [67]. RANKLinduced NF-κB activity controls normal osteoclastogenesis and also plays an important
role in the bone resorbing function of mature osteoclasts [59, 67, 123]. Therefore,
upregulation of RANKL-induced NF-κB signaling could at least in part explain the
increase in osteoclastic activity in PDB [59].
The binding of RANKL and RANK receptor induces receptor trimerization and
recruitment of TRAF6 to bind RANK receptor [124, 125]. P62 subsequently binds to
TRAF6 through its TB motif, and facilitates TRAF6 Lys63-linked polyubiquitination
[126], since TRAF6 is an RING domain-containing E3 ligases [127, 128]. In addition,
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TRAF6 could catalyze the K63-linked polyubiquitination of TAB1-TAB2-TAK1
complex [129], which activates the IκB kinase (IKK). Moreover, atypical protein kinase
C (aPKC) is activated by interaction with p62 through its PB1 domain, and further
activates the IKK [95]. Activated IKK further phosphorylates IκB, and IκB will be
degraded by 26 S proteasome. Transcription factor NF-κB is then released from IκB and
translocates from the cytosol to the nucleus, activating the transcription of target genes
related to the osteoclast formation [130]. The pathway is illustrated in Fig. 1.5. In
addition, Osteoprotegerin (OPG) negatively regulate RANKL-induced NF-κB signaling
by competitive binding of RANKL with RANK receptor [131].
In our study, we studied the impact of PDB-associated p62 mutants on RANKLinduced NF-κB signaling. However, the lack of appropriate cell lines prevented us from
further investigation.

TNFα-induced NF-κB signaling
Tumor necrosis factor α (TNFα) is an important cytokine involved in
inflammation, cellular homeostasis and tumor progression and apoptosis [132, 133].
TNFα-induced NF-κB activation is similar to RANKL-induced NF-κB signaling
discussed above, but also has its own characteristics.
TNFα functions through two receptors, TNF-R1 and TNF-R2 [134]. TNF-R2 is
exclusively expressed only on endothelial and immune cells. TNF-R1 is universally
expressed in many cell types, and has been studied more extensively than TNF-R2 [135].
TNFα binds TNF-R1 and induces receptor trimerization and leading to the recruitment of
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the adaptor protein TNF-R1-associated death domain protein (TRADD) which binds to
the death domain (DD) of TNF-R1[135]. TRADD protein also recruits TNF receptorassociated factor 2 (TRAF2), a family protein with TRAF6 mentioned above. TRAF2 is
an E3 ligase and it could undergo auto-polyubiquitination and ubiquitinates RIP through
K63-linked polyubiquitin chains. RIP polyubiquitination binds to TAB2/TAB3 complex,
and recruit TAK1, which phosphorylates IKK, leading to the activation of the IKK
complex [72]. Moreover, p62 interacts with RIP through its ZZ finger. P62 could also
interact with aPKC through PB1 domain, and thereby activate IKK [72]. Activated IKK
further phosphorylates IκB, and IκB will be degraded by the 26S proteasome.
Transcription factor NF-κB is then released from IκB and translocates from the cytosol to
the nucleus, activating the transcription of target genes [135]. TNFα-induced NF-κB
signaling is illustrated in the Fig. 1.5.
In our study, we investigated the impact of PDB-associated p62 mutations on
TNFα-induced NF-κB singaling. We found that p62 PDB mutants increased TNFαinduced NF-κB signaling compared with WT p62. Additionally, we tried to determine the
molecular mechanisms of the role of p62 PDB mutant in signaling.

Autophagy
In Greek, “autophagy” means “self-eating” [136]. It is another way of protein
degradation, in addition to ubiquitin proteasome system (UPS) [137]. Autophagy is a
process for degradation of cellular contents, organelles, misfolded proteins and invading
bacteria through the lysosomal machinery [138-143]. It contains several different forms,
including macroautophagy, microautophagy and chaperone-mediated autophagy [85].
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Autophagy has emerged as a very active area of investigation as it closely regulates many
cellular functions. Autophagy is also implicated in many diseases, including alcoholic
liver disease, neurodegenerative disease and cancer [138, 144-146].
Inducers and inhibitors of macroautophagy
We focus on macroautophagy in our study. The soluble materials and organelles
in the cytoplasm are sequested by an isolation membrane (also termed “phagophore”).
Autophagosomes are formed by expansion of the isolation membrane. The
autophagosome then fuses with the lysosome to become an autophagolysosome (also
termed “autolysosome”) where the enclosed substrates are degraded (Fig. 1.7 A) [85].
Currently, several autophagy inducers and inhibitors have been widely used (Fig. 1.7 A)
[147]. For example, rapamycin is an inhibitor of the mTOR pathway which negatively
regulates autophagy. Therefore, rapamycin is an inducer for autophagy. NH 4 Cl and
Bafilomycin A inhibit the fusion of lysosome and autophagosome, thereby inhibiting
autophagy. Another common strategy to induce autophagy is starvation [148]. The class
III phosphatidylinositol 3-kinase (PI3K-III) activates autophagy and 3-MA inhibits PI3KIII. Therefore 3-MA is another inhibitor for autophagy. In contrast, beclin-1 activates
PI3K-III. Thus beclin-1 is an inducer for autophagy. Other autophagy inhibitors include
E64d and pepstatin A, which inhibit the protease activity in the autophagolysosome (Fig.
1.7 A).
LC3-II is a marker for autophagosome
LC3 is widely used as an autophagy marker. In yeast, Atg 8 is the homolog of
LC3 in human [149, 150]. There are two forms of LC3, LC3-I and LC3-II, in yeast and
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mammalian

cells.

LC3-I

is

cytosolic,

whereas

LC3-II

is

conjugated

with

phosphatidylethanolamine (PE) and is mainly present in isolation membranes,
autophagosomes and much less on autolysosomes. Therefore, LC3-II serves as a marker
for autophgosomes. The conversion of LC3-I to LC3-II requires the Atg5-Atg12 complex
(Fig. 1.7 B) [151].
It seems that the increase of LC3-II indicates more autophagosome and higher
autophagic activity. However, LC3-II is also degraded by autophagy, making it difficult
to interpret autophagy activity solely based on LC3-II level. Therefore, lysosomal
protease inhibitors (E64d and pepstatin A) and inhibitors for the fusion of lysosome and
autophagosomes (NH 4 Cl and Bafilomycin A) are commonly used in the studies to help
determine whether autophagic activity is truly increased [152]. It is important to compare
the amount of LC3-II in the presence and absence of these inhibitors.
Methods for studying autophagy also include counting the number of GFP-LC3
puncta in cells overexpressing GFP-LC3.

P62 is both a substrate and regulator of autophagy
P62 is a specific substrate of autophagy [153]. It can bind LC3 on the
autophagosome through LIR domain (Fig. 1.4 A) [152]. P62 proteins which have
mutations in LIR region are not degraded by autophagy, result in their accumulation
followed by inclusion formation [8]. Therefore, it is suggested that p62 is degraded by
autophagy through interaction with LC3 directly. In addition, p62 mutations in PB1
domain are defective in oligomerization. Lower autophagic degradation of these p62
mutants indicates that oligomerization of p62 through PB1 are critical for their
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degradation by autophagy [8]. Besides, the level of p62 is upregulated in Atg5 -/- MEFs,
suggesting that accumulation of p62 could serve as an indicator of autophagy suppression
[152]. The steady-state level of p62 has recently been used as a marker of autophagic
degradation activity. For instance, an elevated level of p62 would be interpreted as
inhibition or failure of autophagic activity [154]. However, this involves the critical
assumption that p62 biosynthesis is not itself regulated. It has been reported that p62 can
be induced at the transcriptional level by various stresses including oxidative stress [155,
156] or proteasome inhibition [157]. Thus, caution should be exercised when using the
p62 level as a marker of autophagic activity.
On the other hand, p62 is also a regulator of autophagy. P62 binds the
polyubiquitinated protein aggregates through its UBA domain. P62, which binds
polyubiquitinated proteins, could also oligomerize through PB1 domains. It is indicated
that the interaction of p62 and LC3 is involved in linking polyubiquitinated protein
aggregates to autophagy [8, 106, 158] (Fig. 1.6). Therefore, p62 is not only a substrate for
autophagy, but it also regulates the autophagic activity of other proteins.
In our study, we mainly investigated the impact of PDB-associated p62 mutations
in autophagy.
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Figure 1.1. SUMOylation conjugation pathway. SUMO conjugation needs E1 SUMOactivating enzyme, E2 SUMO-conjugating enzyme (Ubc9) and E3 SUMO ligase, which
is similar to ubiquitin conjugation. SUMO could also be removed by deconjugating
enzymes such as the SENP enzymes. This pictures is modified from a review paper
written by Wilkinson et al. [1].
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Figure 1.2. Nuclear SUMOylation substrates and their functions. The well studied
nuclear SUMOylation substrates could be further classified into nuclear pore complexes,
transcription factors & coregulators, DNA replication & repair proteins and kinetochore
& centromere proteins. A delicate balance between SUMOylation and deSUMOylation is
essential to normal cell functions. This picture is modified from a review paper written
by Zhao [2].
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Figure 1.3. PDB is a disorder of bone remodeling. Bone mass in human being is
controlled by both osteoclasts (bone-resorbing cells) and osteoblasts (bone-forming cells).
The opposing activities of these two cell types ensure bone is constantly remodeled in a
process essential for maintaining adult bone structure and function [59]. PDB is
characterized by focal areas of increased bone turnover containing enlarged hyperactive
osteoclasts [7, 59]. This picture is taken from a review paper written by Layfield (2007)
[59]. This picture is used with a license agreement between Xiaoyan Liu and Cambridge
University Press, with a license number 2822601263692.
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Figure 1.4. Schematic domain structure of p62 and NMR structure of the p62 UBA
domain. (A) P62 has different domains which exhibit diverse functions by interacting
with a number of key proteins. This pictures is modified from a review paper written by
Moscat et al. [90]. (B) Surface representation of the p62 UBA domain determined by
protein NMR. Several representative p62 PDB mutations are shown here. This pictures is
taken from a review paper written by Layfield et al. [111]. Fig. 1.4 B is used with a
license agreement between Xiaoyan Liu and Springer provided by Copyright Clearance
Center, with a license number 2822600493041.

(A)

(B)
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Figure 1.5. RANKL-induced and TNFα-induced NF-κB signaling. Upon RANKL or
TNFα stimulation, TNF-R and RANK receptor undergo trimerization and recruit TRAFs
to membrane. Briefly, NF-κB signaling is involved in TRAFs polyubiquitination, IKK
activation, IκB degradation and NF-κB translocation from cytosol to nucleus and
following target genes expressions. This diagram was drawn in light of a number of
papers [65, 93-95, 130, 135, 159].
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Figure 1.6. P62 is proposed to involve in both ubiquitin proteasome system (UPS)
and autophagy pathway. P62 involves in targeting polyubiquitinated proteins for
degradation by both UPS and autophagy. This picture is modified from a review paper
written by Komatsu et al. [8] with permission. The use of this picture is also permitted
by the FEBS Letters.

Degradation by UPS
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Figure 1.7. Autophagy pathway. (A) The process of autophagy. Autophagy inducers
(shown in red) and autophagy inhibitors (shown in blue) are presented here. This picture
is modified from Dr. Ping Shi’s dissertation in Dr. Haining Zhu’s lab. (B) The conversion
of LC3-I to LC3-II requires the Atg5-Atg12 complex. This picture is modified from a
review paper written by Nedelsky et al. [151].
(A)

(B)

Copyright © Xiaoyan Liu 2012
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Chapter 2. Proteomic analysis of SUMOylated proteins in mammalian cells

Introduction

As described in Chapter 1, SUMOylation of proteins are involved in a number of
diseases including neurodegenerative diseases, cancer and diabetes [14, 160]. Therefore,
it is important to identify the SUMOylation subtrates and investigate the functional
consequences of SUMOylation of these substrates, which might shed light on finding the
therapeutic target for treating these diseases. Identification of SUMOylated proteins has
remained a challenge because of the low abundance of SUMOylation substrates, a small
portion of SUMOylated proteins, in addition to the high activity of SUMO deconjugating
enzymes such as SENP [161]. Quantitative proteomics, using isotope labeling-based
methods, have been used to identify SUMOylation substrates [162]. Knuesel et al. [163]
showed that the SUMO-1(T95R) mutant can be used for the identification of the
SUMOylation site by mass spectrometry in vitro [163]. In light of this study, we
introduced a relatively simple proteomic method without isotope labeling for
identification of SUMOylated proteins, which had not been previously reported.
Furthermore, Knuesel et al. [163] was unable to determine whether this hSUMO1(T95R) mutant was still functional in vivo. In our current study, we demonstrated
whether that this mutant retained its functionality in HEK cells.
Most reported substrates for SUMOylation are nuclear proteins, though a few
cytosolic proteins have been shown to be substrates [24, 36, 164]. Given this lack of
knowledge about cytosolic SUMOylation targets, we were particularly interested in novel
cytosolic protein targets.
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In this Chapter, we aim to identify novel SUMOylation substrates in mammalian
cells by using our newly developed proteomic method. The most important advantage of
our strategy is that, it is an isotope-labeling free method, which is easier compared with
isotope-labeling method. Especially, we expect to identify novel cytosolic protein as
SUMOylation substrates. For the potential novel SUMOylation subtrates identified by
mass spectrometry analysis, we should firstly validate SUMOylation of these proteins by
other methods, such as immunoprecipitation and Western blotting. Next, we need to find
the potential SUMOylation sites of these novel substrates. Finally, we would like to
investigate the functional consequences of these novel SUMOylation substrates.

Materials and methods

cDNA cloning of human SUMO-1 gene
Total RNA was extracted from HEK293 cells using Qiagen RNA extraction kit
following the manufacturer’s instruction. Human SUMO-1 full-length cDNA (“SUMO1-FL”) was amplified with the following two primers containing two restriction sites at
each end: 5’ -GC GGA TCC ATG TCT GAC CAG GAG GCA AAA CC-3’ and 5’-GC
GCGGCCGC CTA AAC TGT TGA ATG ACC CCC TCT TTG- 3’ using cDNA RTPCR amplification kit (Invitrogen). Human SUMO-1 cDNA lacking the last four amino
acids with GG bases at the C-terminal end, was amplified with the following two primers
containing two restriction sites at each end: 5’-GC GGA TCC ATG TCT GAC CAG
GAG GCA AAA CC-3’ and 5’-GC GCGGCCGC CTA AAC TGT TGA ATG ACC CCC
TCT TTG -3’ using cDNA RT-PCR amplification kit (Invitrogen) (“SUMO-1-GG”). The
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amplified PCR products were recovered using a PCR purification kit (Qiagen), digested
with HindIII and BamHI and then ligated into the p3xFLAG-CMV-10 expression vector
(Sigma, St Louis, MO, USA) digested with HindIII and BamHI. The positive clones
containing the correct inserts were sequenced, and were named pCMV-3xFLAG-SUMO1-FL (“SUMO-1 FL” or “FL”, full length) and pCMV-3xFLAG-SUMO-1-GG
(“SUMO1-GG” or “GG”, last four amino acids truncated), respectively.
Plasmids construction
SUMO-1 FL plasmid with the T95R mutation was amplified from the pCMV3xFLAG-SUMO-1-FL construct by PCR using two primers containing the following
sequences: 5’-GC AAG CTT ATG TCT GAC CAG GAG GCA AAA CC-3’ and 5’-GC
GCGGCCGC CTA AAC TGT TGA ATG ACC CCC TCT TTG-3’. SUMO-1 GG (last
four amino acids truncated) with the T95R mutation was amplified from the pCMV3xFLAG-SUMO-1-GG construct by PCR using two primers containing the following
sequences: 5’-GC AAG CTT ATG TCT GAC CAG GAG GCA AAA CC-3’ and 5’-GC
GCGGCCGC CTA ACC CCC TCT TTG TTC CTG ATA-3’. The amplified DNA
fragments were inserted into the HindIII and NotI sites of the pCMV-3xFLAG-10 vector
(Sigma). The positive clones were named “SUMO-1-FL-T95R” (or “FL-T95R”, full
length with T95R mutation) and “SUMO-1-GG-T95R” (or “GG-T95R”, last four amino
acids truncated, with T95R mutation), respectively.
The original Drebrin construct was a gift from Drs. Tomas Brdickac and Ondrej
Hrusaka (Czech Republic) [165]. Drebrin was firstly amplified by PCR by using upper
and lower primers GJ764 and GJ765 (Appendix II). The amplified DNA fragments were
inserted into the EcoRI and BamHI sites of p3xHA-CMV-10, and the positive clones
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containing the correct inserts were sequenced. The positive clones were named p3xHADrebrin (human full-length, WT Drebrin). Drebrin constructs containing various point
mutations were generated using the QuikChange II Site-Directed Mutagenesis Kit
(Stratagene), or Quikchange Multi Mutagenesis Kit (Stratagene) based on p3xHADrebrin (WT). The mutagenic primer sequences are summarized in Appendix II. These
mutations included K185R, K186R, K192R, K270R, K271R, K185R/K186R,
K270/K271R and the Drebrin mutant in which five Lys are mutated to Arg:
K185R/K186R/K192R/K270R/K271R (“5-K mutant”).

Cell culture and transient transfection
Human embryonic kidney 293 (HEK293) cells were maintained at 37°C with 5%
CO 2 in Dulbecco's modified Eagle's medium (Invitrogen) containing 10% fetal bovine
serum (FBS), 100 units/ml penicillin and 100 µg/ml streptomycin. Chinese hamster ovary
(CHO) cells were cultured in classical liquid media: Hams nutrient mixture F12
( SH3052601;Thermo scientific, HyClone).
For protein identification by mass spectrometry, 50% confluent cells were
transfected with the four different 3xFLAG-SUMO-1 constructs mentioned above, and
the p3xFLAG-CMV-10 control vector using lipofectamine transfection reagent
(Invitrogen) in a 10cm plate format. For Ran-GAP1 SUMOylation verification by FLAG
immunoprecipitation (IP), 70% confluent cells were transfected with FLAG-SUMO-1
(FL) in a 6-well plate format. For Drebrin SUMOylation verification by FLAG and HA
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IP, 70% confluent cells were transfected with 3xHA-Drebrin (WT) and the different
mutant 3xHA-Drebrin constructs in a 6-well plate format.

In-gel digestion and gel extraction
After FLAG-IP, enriched SUMOylated proteins were subjected to 10% SDSPAGE. The gel was washed twice with fix buffer (50% methanol and 7% acidic acid),
and was then stained with SYPRO Ruby (S-12000; Invitrogen) overnight (Fig. 2.2). The
next day, the gel was washed twice with wash buffer (10% methanol and 7% acidic acid).
Each lane of gel was cut into seven or eight bands, and these bands were subsequently cut
into the small pieces. These gel pieces were then washed three times with 50% ACN,
25mM NH 4 HCO 3 (AMBIC) pH 8.0, dried with a SpeedVac and reduced with 10mM
DTT/50mM AMBIC at 56°C for 45 minutes. Next, proteins were alkylated with 55mM
IAA/50mM AMBIC at room temperature for 30 minutes in the dark. Following the wash
with 25mM AMBIC, the gel pieces were dehydrated with 100% ACN and then dried
using a SpeedVac for 10 minutes. The gels pieces were then incubated with 10ng/µl
trypsin in 25mM AMBIC overnight at 37°C. The resulting peptides were extracted using
200µl 50% ACN and 5% formic acid. The extraction liquid was subsequently transferred
into a new 0.5ml low retention tube and concentrated to 20 µl.
Mass spectrometry analysis
The peptides were subjected to Liquid Chromatography/Mass Spectrometry/Mass
Spectrometry (LC-MS/MS) analysis, and the electrospray MS/MS data were collected
from a Q-Star XL quadruple time-of-flight (TOF) mass spectrometer (ABI/MDS Sciex,
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Foster City, CA, USA) using a nano-flow HPLC system (Eksigent, Dublin, CA, USA).
For direct infusion electrospray ionisation- mass spectrometry (ESI-MS) analysis, the
sample was diluted 10 times with 90% acetonitrile containing 0.1% formic acid and
loaded to Au/Pd-coated spray emitter (Proxeon, Odense, Denmark). The electrospray
voltage was 2100 V and the mass range of TOF MS was from 350 to 1600 (m/Z). Nanoflow LC-MS/MS was performed by exploiting the nano-HPLC system for sample pickup and separation, where the desired volume of sample solution was injected by the
autosampler, desalted on a trap column (300 µm i.d. x 5 mm; LC Packings), and was then
subsequently separated by reverse phase C18 column (75 µm i.d. x 150mm; Vydac) at a
flow rate of 200 nL/minutes. The HPLC gradient was linear from 5% to 75% in 55
minutes using mobile phase A (H 2 O, 0.1% formic acid) and B (80% acetonitrile, 0.1%
formic acid). Data acquisition was performed using information-dependent mode, where
each cycle typically consisted of a 1s TOF MS survey from 350 to 1600 (m/z) and two 2s
MS/MS scans with mass range of 100-1600 (m/z).
Protein identification and data analysis
LC-MS/MS data were subjected to database searches for protein identification
using a local MASCOT search engine, and candidate proteins were generated by
searching the Swiss-Prot database. LC-MS/MS data were also submitted to the MASCOT
server for MS/MS ion search, and the peak lists from the LC-MS/MS spectra were
generated by the MASCOT script embedded in the Analyst QS software using the
following parameters: no smoothing, charge state determined from the MS scan,
precursor ion charge states of 2+ and 3+, centroid MS/MS data, height percentage 50%
and merge distance 0.02 Da. The typical parameters used in the MASCOT MS/MS ion
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search are: Homo sapiens, maximum of three trypsin missed cleavages, “Ubi-GG-Lys”
definition, cysteine carbamiodomethylation, methionine oxidation, protein N-term
Acetylation, a maximum of 100 ppm MS error tolerance and a maximum of 0.5 Da
MS/MS error tolerance. For MS/MS ion search, proteins with one peptide ion scoring
higher than 20 were considered an unambiguous identification without manual inspection.
All other hits were manually verified by confirming the peptide sequences from the
MS/MS spectra. Non-specific proteins from empty vector were eliminated from the
protein list generated from other four different SUMO-1 samples.

Gene ontology (GO) database
The identified common SUMOylated protein list was subjected to the Gene
Ontology (GO) database, and these proteins were classified based on their location of the
cell. These locations included nucleus, cellular membrane, cytosol, cytoskeleton,
chromosome, mitochondrion, extracellular and unannotated location.

Immunoprecipitation
Forty-eight hours after transfection, cells were washed with 1x phosphate-buffered
saline (PBS) and lysed using 1x radio immunoprecipitation assay (RIPA) buffer
(Millipore) supplemented with protease inhibitor cocktail (P-8340; Sigma, St Louis, MO,
USA), 0.625 mg/mL N-ethylmaleimide (Sigma), 1 mM sodium o-vanadate (Sigma) and
0.2 mM phenylmethylsulfonyl fluoride (Sigma).

38

The FLAG immunoprecipitations were performed by anti-FLAG M2 affinity gel
(F2426; Sigma) in a final volume of 500 μl containing 1 mg protein extract. The IP
samples and the corresponding extracts were subjected to sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) followed by Western blotting using the
following antibodies: anti-Ran-GAP1 (gift from Dr. Kevin Sarge, University of
Kentucky), anti-FLAG (A8592; Sigma), anti-actin (sc-1616; Santa Cruz Biotechnology)
and anti-HA (mouse, sc-7392; Santa Cruz Biotechnology).
The hemagglutinin (HA) IPs were performed by using 2 μg of a mouse monoclonal
anti-HA antibody (mouse, sc-7392; Santa Cruz Biotechnology) and Protein-G Sepharose
(17-0618-01; GE Healthcare). The IP samples and the corresponding extracts were then
subjected to SDS-PAGE followed by Western blotting using the following antibodies:
anti-FLAG (A8592; Sigma), anti-actin (sc-1616; Santa Cruz Biotechnology) and anti-HA
(rabbit, sc-805; Santa Cruz Biotechnology).

Western blotting and quantification
Nitrocellulose membrane was incubated in blocking solution, 5% milk in TrisBuffered Saline and Tween 20 (TBST) for one hour. Then the membranes were incubated
with primary antibody for more than three hours. After four washes with TBST for five
minutes each, the membrane was incubated with the secondary antibody for more than
one hour. After four washes again with TBST for five minutes each, proteins of interest
were visualized by either normal or dura enhanced chemiluminescent (ECL) substrate
(Thermo scientific) for detection of horseradish peroxidase (HRP) enzyme (Thermo
scientific). The membrane was covered with the wrapping membrane and an
autoradiography film (Denville Scientific) which was exposed to the membrane. The
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exposure time varied from one second to 20 minutes depending on the signal intensity.
Films were subsequently developed by a Kodak X- OMAT 2000 processor.
Software Image J was used for quantification of Western blotting bands on X-ray
films. Since ECL signals of the Western blot were captured on X-ray films which are
known to have a narrow linear range of detection, the quantification of the Western blot
may be out of linear range for certain experiments. Enhanced chemofluorescence (ECF)
substrate and Alkaline Phosphatase (AP)-conjugated secondary antibody are encouraged
for use in the future.

Bioinformatic analysis
SUMOylation sites were predicted using the online software SUMOsp 2.0
(http://www.sumosp.biocuckoo.org/prediction.php). This software was used to analyze
all the candidate SUMOylated proteins in the list (Table 2.1). In addition, AlignX Module
Vector NTI (Invitrogen) was used to align the predicted SUMOylated region of human
(Homo sapiens), mouse (Mus musculus), rat (Rattus norvegicus), rabbit (Oryctolagus
cuniculus), horse (Equus caballus), cattle (Bos taurus), african elephant (Loxodonta
africana), giant panda (Ailuropoda melanoleuca), domestic dog (Canis familiaris),
opossum (Monodelphis domestica), chicken (Gallus gallus), lizard (Anolis carolinensis),
african clawed frog (Xenopus laevis) and zebrafish (Daniorerio) (Fig. 2.7 C).

Immunostaining and confocal microscopy
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Chinese hamster ovary (CHO) cells at 30%-40% confluency were transfected
with HA-Drebrin (WT and mutants) using lipofectamine reagent (Invitrogen) on gelatincoated coverslips. Twenty-four hours post-transfection, cells were fixed with 4%
paraformaldehyde (PFA) at 37 °C for 15 minutes, permeabilized with PBS/0.1% Triton,
and blocked with 3% bovine serum albumin (BSA) in PBS for 1 hour. All the primary
and secondary antibodies were diluted in 3% BSA/PBS. Cells were first stained with
primary antibody HA (mouse, sc-7392; Santa Cruz Biotechnology, 1:300) or Drebrin
(ab11068; Abcam, 1:100) for 5.5 hours. The coverslips were then washed with PBS and
incubated with 4’,6-diamidino-2-phenylindole (DAPI) (D9542; Sigma, 2mg/ml, 1:2000),
Oregon Green 488 phalloidin (Invitrogen, 1:50), secondary antibody Alexa Fluor 594
anti-mouse (A21203; Invitrogen 1:300), or Alexa Fluor 594 anti-rabbit, (A11012;
Invitrogen 1:300) for 1 hour. Finally, the coverslips were mounted using Vectashield
mounting medium (Vector Laboratories). Fluorescence microscopy was used by a Leica
SP5 inverted confocal microscope with a 40X objective.

Protrusion quantification and statistical analysis
For each sample, 10 view images with Z-stack were taken by a Leica SP5
inverted confocal microscope with a 40X objective. Each view contained about 20-30
cells. The numbers of protrusions were counted for each cell which has protrusions. The
percentage of cells with protrusions was counted. The data were presented as mean with
standard deviation (SD) based on these 10 view images. The significant differences in
percentage of cells with protrusions between cells expressing WT Drebrin and mutant
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Drebrin were analyzed by one-way ANOVA, with Tukey’s post-test using the software
GraphPad Prism 5 Demo.

Results
Generation of different versions of 3xFLAG-SUMO-1 fusion protein

The arginine residue at the C-terminus of ubiquitin could be recognized and
cleaved by trypsin, leaving a diglycine signature peptide for identification of
ubiquitination site by mass spectrometry [166, 167]. However, for human SUMO-1, the
C-terminal end is “TGG” instead of “RGG”, thus it is impossible to generate the
diglycine signature peptide. In addition, the last lysine or arginine residues of SUMO-1
are considerably distant from the C-terminus end, generating a SUMO tag
(ELGMEEEDVIEVYQEQTGG) that is too big for detection by tandem mass
spectrometry.
To solve this problem, we mutated the Thr95 residue of SUMO-1 to Arg. Thus, if
endogenous SENPs in HEK293 cells correctly recognize and process the mutant
construct, the last four amino acids of SUMO-1 will be removed. This cleavage of
SUMO-1 (“FL-T95R”) would yield a 114.1 Da diglycine signature tag (“GG-tag”)
following trypsin digestion, which could be used for identification of SUMOylation site
with high confidence. Considering that endogenous SENP might not work efficiently to
remove the last four amino acids of SUMO-1, we also removed the last four amino acids
manually to generate the “SUMO-1-GG” (“GG”, last four amino acids truncated) and
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“SUMO-1-GG-T95R” (“GG-T95R”, last four amino acids truncated, with T95R
mutation) (Fig. 2.1).

Identification and classification of SUMOylated proteins from HEK293 cells
overexpressing four different versions of SUMO-1

SUMOylated proteins were immunoprecipitated from cell lysates of HEK293
cells overexpressing four different FLAG tagged SUMO-1 plasmids including “FL” (full
length), “FL-T95R” (full length with T95R mutation), “GG” (last four amino acids
truncated) and “GG-T95R” (last four amino acids truncated, with T95R mutation). The
enriched SUMOylated proteins were then subjected to in-gel digestion, and the resulting
peptides were extracted and subjected to LC-MS/MS analysis. The LC-MS/MS data
were subsequently subjected to MASCOT MS/MS ion search.
Proteins with one peptide ion scoring higher than 60 or two peptide ions scoring
higher than 30 were considered unambiguous identification without manual inspection.
The ion score filter is 20. All other hits were manually verified by confirming the peptide
sequences from the MS/MS spectra. Non-specific proteins from control samples were
eliminated from all other four samples. The number of proteins identified in cells
expressing “FL” SUMO-1 (full length), “FL-T95R” SUMO-1 (full length with T95R
mutation), “GG” SUMO-1 (last four amino acids truncated) and “GG-T95R” SUMO-1
(last four amino acids truncated, with T95R mutation) are 129, 213, 217 and 177,
respectively (Fig. 2.3 A). There are 74 identified common SUMOylated proteins among
these four samples (Table 2.1). In these 74 proteins, two proteins have GG-tag. One is
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Ran GTPase-activating protein 1 (Ran-GAP1) (RAGP1_HUMAN), the other is Tcomplex protein 1 subunit delta (TCP-1-delta) (TCPD_HUMAN) (Table 2.2).
Additionally, there are 88 common proteins identified from cells overexpressing “FL”
SUMO-1 (full length) and “GG-T95R” SUMO-1 (last four amino acids truncated, with
T95R mutation) (Fig. 2.3 B).
As described above, a total of 177 unique proteins were identified from the
purified SUMOylated proteins in cells overexpressing “GG-T95R” SUMO-1 (last four
amino acids truncated, with T95R mutation) (Fig. 2.3 A). There were 13 proteins
identified with GG-tag from cells overexpressing “GG-T95R” SUMO-1 (last four amino
acids truncated, with T95R mutation) when cutoff was 20 (Table 2.2).
The above 74 identified common SUMOylated proteins were classified by
subcellular location using the Gene Ontology (GO) databases, and these proteins were
classified into nucleus, membrane, cytosol, cytoskeleton, chromosome, mitochondrion,
extracellular and unannotated (Fig. 2.4). Among these 74 identified common
SUMOylated proteins, most protein (51.4%) were located in the nucleus, 28.4% protein
were located into membrane, 21.6% protein were located in the cytosol, 16.2% protein
were located in the cytoskeleton, 12.2% protein were located in the chromosome, 9.5%
protein were located in the mitochondrion, 6.8% protein were extracellular and 6.8%
protein were unannotated (Fig. 2.4).

Validation of Ran-GAP1 SUMOylation by MS/MS spectra and IP
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Ran-GAP1 was the first identified SUMOylated protein [12] and was also in our
candidate SUMOylation protein list (Table 2.1). Thus, we have again validated RanGAP1 SUMOylaton using MS/MS spectra (Fig. 2.5) and IP (Fig. 2.6). The successful
validation of Ran-GAP1 could serve as a positive control for our proteomic method.
First, we validated Ran-GAP1 SUMOylation by MS/MS spectra. If Ran-GAP1 is
SUMOylated, after trypsin digestion, it will generate a peptide with a GG-tag. Then after
fragmentation, it will generate a lysine residue (128.09 Da) with two glycine residue
(114.04 Da), a total 242.1379 Da. Indeed, here we found the MS/MS spectra of peptide
LLVHMGLLK*(GG)SEDK derived from digestion of Ran-GAP1. This peptide was
fragmented into a, b, c, x, y and z series ions. The molecular weight of y4 ion is 478.1643
and molecular weight of y5 ion is 720.2861. The difference between y4 and y5 ion is
242.1218, which is exactly the molecular weight of lysine and two glycine mentioned
above, representing the GG tag generated by trypsin digestion (Fig. 2.5). Therefore, it is
shown that Ran-GAP1 is SUMOylated by MS/MS spectra.
Next, HEK293 cells were transfected with “FL” SUMO-1 (full length) or “GGT95R” SUMO-1 (last four amino acids truncated, with T95R mutation). Forty-eight
hours post-transfection, FLAG-SUMO-1 IP was performed, and IP products were
subjected to SDS-PAGE. Western blotting was performed using antibodies against RanGAP1, FLAG and actin. SUMOylated Ran-GAP1 was shown in IP products from cells
overexpressing either “FL” SUMO-1 or “GG-T95R” SUMO-1, but not in the control
samples (Fig. 2.6). Therefore, it is again shown that Ran-GAP1 is SUMOylated by IP and
Western blotting.
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Identification and validation of SUMOylation of a novel substrate named Drebrin

We also used the software SUMOsp 2.0 to predict SUMOylation sites for all the
candidate SUMOylation proteins in our list (Table 2.1). Among these 74 common
proteins, 40 proteins (54%) have SUMOylation consensus sequences, 61 proteins (82%)
have predicted SUMOylation sites including both SUMOylation consensus sites and nonSUMOylation consensus sites (Table 2.1).
Our candidate SUMOylation protein list (Table 2.1) includes a protein called
Drebrin. As described in Chapter 1, Drebrin is an actin-binding protein involved in the
formation of neurites and cell protrusions [44]. Unlike nuclear proteins that comprise the
majority of SUMOylation substrates, Drebrin is a cytosolic actin-binding protein [45, 56].
The SUMOsp2.0 software showed that Drebrin had four predicted SUMOylation sites, in
which one is a SUMOylation consensus motif, and the other three are non-consensus type
(Table 2.1 and Fig. 2.7 A). We also aligned this predicted SUMOylated region among
different species. This region was shown to be highly conserved among vertebrate
species, suggesting that this region is functionally important (Fig. 2.7 C). Consistently, a
previous report states that the Drebrin protein is highly conserved, especially at the Nterminal (residues 1-315) [44].
We verified Drebrin SUMOylation by both FLAG-SUMO-1 IP and HA-Drebrin IP.
In detail, we first verified Drebrin SUMOylation by FLAG-SUMO-1 IP. HEK293 cells
were transfected with “FL” SUMO-1 (full length) or “GG-T95R” SUMO-1 (last four
amino acids truncated, with T95R mutation). Forty-eight hours post-transfection, FLAG46

SUMO-1 IP was performed and IP products were subjected to SDS-PAGE. Western
blotting was performed using antibodies against Drebrin with longer and short exposure
time. SUMOylated Drebrin is shown in both cells expressing “FL” SUMO-1 and “GGT95R” SUMO-1, not in the control cells (Fig. 2.8 A, long exposure), suggesting that
Drebrin is SUMOylated by FLAG-SUMO-1 IP. Also, the SUMOylation level of Drebrin
is higher in cells expressing “FL” SUMO-1 than “GG-T95R” SUMO-1 (Fig. 2.8 A).
In addition, we verified Drebrin SUMOylation by HA-Drebrin IP. HEK293 cells
were transfected with HA-Drebrin (WT) and FLAG-SUMO-1 (full length). Forty-eight
hours post-transfection, HA-Drebrin IP was performed and IP products were subjected to
SDS-PAGE. Western blotting was performed using antibodies against FLAG, HA and
actin. SUMOylated Drebrin was observed in cells expressing both HA-Drebrin and
FLAG-SUMO-1, but not in control cells (Fig. 2.8 B), indicating that Drebrin is
SUMOylated by HA-Drebrin IP.

K185, K186, K270 and K271 are potential SUMOylation sites of Drebrin

We next aimed to find potential SUMOylation sites of Drebrin. According to the
SUMOylation consensus sequence ΨKXE/D [1], Drebrin has four predicted
SUMOylation sites including one SUMOylation consensus site, AKKE (amino acid 184187) and three non-consensus sites, which are KKEE (amino acid 185-188), RKEE
(amino acid 191-194) and KKSE (amino acid 270-273) (Fig. 2.7 B). These sites are also
conserved among a number of different species (Fig. 2.7 C).
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By using the site-directed mutagenesis, we generated several Drebrin single
mutants through changing the K185, K186, K192, K270 and K271 of Drebrin to R
respectively. Also, we generated double mutants including K185R/K186R and
K270R/K271R. Additionally, we generated a mutant in which all the five K are mutated
to R, K185R/K186R/K192R/K270R/K271R, called “5-K mutant”.
Then, we performed both FLAG-SUMO-1 IP and HA-Drebrin IP in HEK293 cells
overexpressing FLAG-SUMO-1 (full length) and a variety of different HA-Drebrin
mutants including double mutations K185R/K186R, K270R/K271R, single mutant
K192R and “5-K mutant” in which all the five K were mutated to R. IP products were
subjected to SDS-PAGE and Western blotting was performed using antibodies against
HA, FLAG and actin (Fig. 2.9 A and B). Interestingly, the SUMOylation level of mutant
Drebrin (combined mutations K185R/K186R) was much less (50% reduction) than that
of WT Drebrin (Fig. 2.9 B, lane 3). Also, the SUMOylation level of mutant Drebrin
(combined mutations K270R/K271R) was slightly less (30% reduction) than that of WT
Drebrin (Fig. 2.9 B, lane 5).
Therefore, these data suggest that potential Drebrin SUMOylation sites could be
K185, K186, K270 and K271. To further clarify which K is SUMOylated, we performed
the HA-Drebrin IP using the single Drebrin mutant, our preliminary data showed that no
single lysine mutant (K185R, K186R, K270R or K271R) could abolish the SUMOylation
level of Drebrin (data not shown). Clarification of this issue requires additional
experiments.
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Double mutation (K185R/K186R and K270R/K271R) in Drebrin separately did not
appear to change protrusion formation

As described in Chapter 1, previous studies have demonstrated that Drebrin plays
an important role in the formation of filopodia [53, 54, 57]. Also, we have shown that
mutant K185R/K186R and K270R/K271R impair Drebrin SUMOylation compared with
WT Drebrin. The next questions would be whether these two mutants also change the
formation of filopodia compared with WT Drebrin. In order to address this question,
CHO cells were transfected with HA-Drebrin (WT, K185R/K186R or K270R/K271R).
Twenty-four hours post-transfection, immunostaining was performed using either HA or
Drebrin antibody for staining Drebrin, Oregon Green 488 phalloidin for staining actin
and DAPI for staining nucleus. Confocal microscopy was used to observe cellular
protrusions (Fig. 2.10 A).
Consistent with the literature [53, 54, 57], we observed obvious cellular protrusions
in cells overexpressing Drebrin (WT and mutants) (Fig. 2.10 A). However, after we
quantified the percentage of cells with protrusions from 10 view images (each image was
selected from five Z-stack images) for each sample, we found that there was no
significant change among cells expressing WT Drebrin and Drebrin mutants (Fig. 2.10 B).
Therefore, our preliminary results suggested that mutation of these two sites
(K185R/K186R and K270R/K271R) in Drebrin separately did not appear to change
protrusion formation.
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Discussion

An applicable proteomic method for identification of SUMO substrates

Previous proteomic method for identification of SUMO substrates is using
isotope-labeling method, which is complex [162]. In this Chapter, we developed a
relatively simple proteomic method to identify SUMOylated proteins in HEK293 cells
based on previous studies [163, 167]. First, we generated a number of SUMO-1
constructs to facilitate identification of SUMOylated proteins by mass spectrometry. In
detail, we mutated the Thr95 of SUMO-1 to Arg (“FL-T95R” SUMO-1, full length, with
T95R mutation). Since endogenous SENPs remove the last four amino acids of SUMO-1,
it could yield a GG-tag after trypsin digestion and facilitate the identification by mass
spectrometry [163, 167]. Considering that SENPs may not work very efficiently, we
further removed the last four amino acids manually, and generated “GG-T95R” SUMO-1
(last four amino acids truncated, with T95R mutation). For comparison, we also
generated a SUMO-1 plasmid without the last four amino acids but retained Thr 95,
called “GG” SUMO-1 (last four amino acids truncated). Together with full length
SUMO-1 (“FL”), these four different versions of SUMO-1 are all FLAG tagged (Fig. 2.1),
and served for enriching SUMOylated proteins by FLAG-IP. The IP products were
subjected to in-gel digestion and mass spectrometry for analysis.
After eliminating the non-specific proteins, 74 common SUMOylated proteins
were identified from cells expressing four different SUMO-1 constructs. These 74
proteins are considered as candidate SUMOylated proteins. In this protein list, three
proteins were reported before as SUMOylation substrates including Ran-GAP1 [12],
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nucleophosmin (NPM) [168] and proliferating cell nuclear antigen (PCNA) [169] (Table
2.1). Also, 16 proteins were found in the articles related to the SUMOylation in PubMed
database. In addition, we predicted SUMOylation sites including SUMO consensus sites
(ΨKXE/D) and non-consensus sites for all these 74 proteins using software SUMOsp 2.0.
The numbers of consensus and non-consensus sites of each protein are shown in Table
2.1. Among these 74 common proteins, 40 proteins (54%) have SUMOylation consensus
sequences, and 61 proteins (82%) have predicted SUMOylation sites including
SUMOylation consensus sites and non-SUMOylation consensus sites (Table 2.1).
Additionally, 51.4% of these 74 identified common SUMOylated proteins are nuclear
proteins, consistent with the observations that most identified SUMOylated proteins are
located within the nucleus [2]. Moreover, we successfully verified the SUMOylation of
Ran-GAP1, the first identified SUMOylation substrate [37] in our system by MS/MS
spectra (Fig. 2.5) and IP (Fig. 2.6). The successful validation of Ran-GAP1 could serve
as a positive control for our proteomic method. Altogether, we have developed an
applicable proteomic method for identification of SUMO substrates.

A novel substrate for SUMOylation, a cytosolic protein called Drebrin

Currently, not many cytosolic SUMOylation substrates have been found [24, 36].
To fill this gap, we identified and validated SUMOylation of a cytosolic protein, called
Drebrin. In our study, we identified a novel cytosolic SUMO substrate, Drebrin. We
verified Drebrin SUMOylation by both FLAG-IP and HA-IP in HEK293 cells
overexpressing FLAG-SUMO-1 and HA-Drebrin (Fig. 2.8 A and B). Drebrin has four
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predicted SUMOylation sites including one SUMOylation consensus site, AKKE (amino
acids 184-187) and three non-consensus sites, which are KKEE (amino acids 185-188),
RKEE (amino acids 191-194) and KKSE (amino acids 270-273) (Fig. 2.7 B). These sites
are also conserved among a number of different species (Fig. 2.7 C).
In order to find potential SUMOylation sites of Drebrin, we generated several
Drebrin single mutants through changing the K185, K186, K192, K270 and K271 to R
respectively. Also, we generated double mutants including K185R/K186R and
K270R/K271R. Additionally, we generated a mutant in which all the five K are mutated
to R, K185R/K186R/K192R/K270R/K271R, called “5-K mutant”. Next, we compared
the effect of SUMOylation in cells overexpressing these HA-Drebrin mutants and WT
HA-Drebrin by HA-IP. Our data showed that the SUMOylation level of Drebrin K185R/
K186R was much less than that of WT Drebrin (Fig. 2.9 B, lane 3), about 50% decrease.
Plus, the SUMOylation level of Drebrin K270R/ K271R is slightly less than that of WT
Drebrin (Fig. 2.9 B, lane 5), about 30% decrease.
We are also curious about the functional consequence of SUMOylated Drebrin. It
was reported that overexpressing Drebrin in CHO cells could cause the formation of
cellular membrane protrusions [53]. Therefore, we investigated the effect of SUMOylated
Drebrin on these CHO cells by overexpressing either WT HA-Drebrin or double mutant
HA-Drebrin (K185R/K186R and K270R/K271R). Consistent with the literature [53, 54,
57], we observed obvious membrane protrusions in cells overexpressing Drebrin (WT
and mutants). However, after we quantified the percentage of cells with protrusions from
10 view images (each image was selected from five Z-stack images) for each sample,
there was no significant change among cells expressing WT Drebrin and Drebrin mutants
52

(Fig. 2.10 B). Thus, our data suggests that mutation of these two sites (K185R/K186R
and K270R/K271R) separately did not appear to change protrusion formation.

Troubleshooting and further technique development

Although our proteomic method is applicable as discussed before, several problems
still remain. Firstly, among the 177 unique proteins identified from the purified
SUMOylated proteins in cells overexpressing SUMO-1 (GG-T95R) (Fig. 2.3 A), there
were only 13 protein identified with GG-tag when cutoff was 20 (Table 2.2).
Additionally, only two of these 13 proteins were in the 74 common protein list (Table 2.1
and 2.2). Moreover, the evidence of MS/MS spectra for GG-tag was not obvious except
for Ran-GAP1 (Fig. 2.5). Therefore, GG-tag might not be easy for identification by
current LC-MS/MS settings. It might due to majority identification of the GG-tags are
below the current limit of detection. Potential ways to overcome this problem could be
increasing the amount of enriched SUMOylated proteins subjected to LC-MS/MS by
increasing cultured cells. Also, more advanced mass spectrometry might help to better
identify the GG-tag.
Another potential problem of our method is that the FLAG-IP is not very specific
for enrichment of SUMOylated proteins. Although proteins in control cells were
eliminated, the enriched SUMOylated proteins by FLAG-IP might still be contaminated
with proteins containing other post-translational modification, such as ubiquitination,
which is very similar to SUMOylation. If so, it is difficult to distinguish SUMOylation
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from ubiquitination in the identified proteins containing GG-tags because they both will
have GG-tags following tryptic digestion. One way to get around this problem could be
using tandem affinity purification (TAP) for better enrichment of SUMOylated proteins.
A third concern is that the “5-K mutant” Drebrin in which all the five Lys are
mutated to Arg did not completely abolish SUMOylation compared with WT Drebrin by
HA-IP (data not shown). Therefore our data suggest that other Lys outside of the
predicted SUMOylation region (Fig. 2.7 B) might be present. Another possibility is that
cells have “compensation mechanism”, thus SUMOylation could occur at some random
Lys when all the SUMOylated Lys are mutated. In addition, the experiments shown in
Fig. 2.9 B were repeated three times. SUMOylation of K185R/K186R mutant Drebrin
decreased compared with WT p62 for all three experiments. However, K270R/271R
mutant Drebrin did not decrease for all three experiments, suggesting again that
SUMOylation sites might be outside of the predicted SUMOylation region. Clarification
of this issue requires additional experiments.

Significance of this study and future directions

Based on a previous study [163], we developed a relatively simple proteomic
method to identify SUMOylated substrates. We have identified 74 SUMOylated proteins
by our method, in which three proteins are reported to be SUMOylation substrates, 16
proteins are related to the SUMOylation substrates, 40 proteins have SUMOylation
consensus sequences (ΨKXE/D) and 61 proteins have predicted SUMOylation sites by
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software. We also validated the first SUMOylated protein Ran-GAP1 in our system.
Therefore, our method is applicable for identifying novel SUMOylation substrates.
In addition, we are the first group to report that an actin-binding protein, Drebrin,
is a substrate for SUMOylation. It is interesting that Drebrin is not in the nucleus, and
little is known about SUMO substrates located outside of nucleus [24, 36]. These data
may expand our knowledge of non-nuclear SUMOylation substrates by studying the
functional consequence of Drebrin. In our study, we verified Drebrin SUMOylation by IP
and found that K185, K186, K270 and K271 might be Drebrin SUMOylation sites. Also,
our data have shown that double mutation (K185R/K186R and K270R/K271R)
separately did not appear to change protrusion formation (Fig. 2.10 B). Therefore, we
could further explore the functional consequences of Drebrin in the future.
Moreover, in our protein list, there are several proteins that have a relatively high
number of predicted SUMOylation sites (highlighted in Table 2.1). These proteins
include general transcription factor II-I (four consensus and two non-consensus sites),
heterogeneous nuclear ribonucleoproteins C1/C2 (two consensus and eight nonconsensus sites), heterogeneous nuclear ribonucleoprotein U (three consensus and five
non-consensus sites), heterogeneous nuclear ribonucleoprotein D0 (one consensus and
three non-consensus sites), nucleolin (four consensus and four non-consensus sites), poly
[ADP-ribose] polymerase 1 (five consensus and 11 non-consensus sites), 60S ribosomal
protein L24 (two consensus and two non-consensus sites) and spectrin beta chain, brain 1
(three consensus and 13 non-consensus sites), Ras GTPase-activating-like protein
IQGAP1 (four consensus and 11 non-consensus sites), ATP-dependent DNA helicase 2
subunit 1 (two consensus and four non-consensus sites) and myosin-10 (six consensus
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and 10 non-consensus sites), another cytosolic protein. Future studies could validate
whether these proteins above are SUMOylation substrates by IP and other methods.
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Figure 2.1. Schematic diagrams of SUMO-1 constructs in our study. Schematic
diagrams of four p3xFLAG-SUMO-1 constructs used in our study including “FL” (full
length), “FL-T95R” (full length with T95R mutation), “GG” (last four amino acids
truncated) and “GG-T95R” (last four amino acids truncated, with T95R mutation).
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Figure 2.2. Sypro Ruby staining SDS-PAGE gel of FLAG-SUMO-1 IP from cells
overexpressing four versions of SUMO-1 constructs. HEK293 cells were transfected
with four different SUMO-1 constructs including “FL” (full length), “FL-T95R” (full
length with T95R mutation), “GG” (last four amino acids truncated) and “GG-T95R”
(last four amino acids truncated, with T95R mutation). Forty-eight hours posttransfection, FLAG-SUMO-1 IP was performed and IP products were subjected to SDSPAGE. The gel was then stained with Sypro Ruby overnight. Each lane was cut into
seven or eight bands and the gel was subjected to the in-gel digestion, gel extraction and
LC-MS/MS.
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Figure 2.3. Number of identified SUMOylated protein from HEK293 cells
overexpressing four different versions of SUMO-1 constructs. (A) Numbers of
SUMOylated proteins identified with high confidence (ion score filter 20) from HEK293
cell overexpressing four different versions of SUMO-1 constructs including “FL” (full
length), “FL-T95R” (full length with T95R mutation), “GG” (last four amino acids
truncated) and “GG-T95R” (last four amino acids truncated, with T95R mutation). There
are 74 common SUMOylated proteins. Non-specific proteins from control samples were
eliminated from identified SUMOylated proteins. (B) Number of SUMOylated proteins
identified with high confidence (Ion score filter 20) from HEK293 cell transfected with
“FL” (full length) and “GG-T95R” (last four amino acids truncated, with T95R mutation).
There are 88 common SUMOylated proteins.
(A)

(B)
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Figure 2.4. Classification of 74 identified common SUMOylated proteins. The 74
common proteins were classified based on the subcellular locations including nucleus,
membrane, cytosol, cytoskeleton, chromosome, mitochondrion, extracellular and
unannotated locations by Gene Ontology (GO) databases. The percentage of proteins
belonging to each subcellular location is also shown.
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Figure 2.5. MS/MS evidence of SUMOylated peptide from Ran-GAP1. MS/MS
spectrum of the peptide LLVHMGLLK*(GG)SEDK derived from digestion of Ran
GTPase-activating protein 1 (Ran-GAP1). Validation of Ran-GAP1 serves as a positive
control for our proteomic method.
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Figure 2.6. Validation of SUMOylated Ran-GAP1 by FLAG-SUMO-1 IP followed
by Western blotting. HEK293 cells were transfected with “FL” SUMO-1 (full length) or
“GG-T95R” SUMO-1 (last four amino acids truncated, with T95R mutation). Forty-eight
hours post-transfection, FLAG-SUMO-1 IP was performed and IP products were
subjected to SDS-PAGE. Western blotting was performed using antibodies against RanGAP1, FLAG and actin.
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Figure 2.7. Predicted SUMOylation region of human Drebrin. (A) Predicted
SUMOylation region of human Drebrin by software SUMOsp 2.0. (B) The predicted
SUMOylation consensus site is highlighted and the predicted non-consensus
SUMOylation sites are underlined. The predicted SUMOylated Lys residues are shown in
red. (C) The sequence alignment of predicted SUMOylation region of Drebrin among
different species including human (Homo sapiens), mouse (Mus musculus), rat (Rattus
norvegicus), rabbit (Oryctolagus cuniculus), horse (Equus caballus), cattle (Bos taurus),
african elephant (Loxodonta africana), giant panda (Ailuropoda melanoleuca), domestic
dog (Canis familiaris), opossum (Monodelphis domestica), chicken (Gallus gallus),
lizard (Anolis carolinensis), african clawed frog (Xenopus laevis) and zebrafish (Danio
rerio).

(A)

(B)
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(C)
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Figure 2.8. Validation of SUMOylated Drebrin by FLAG-SUMO-1 IP and HADrebrin IP followed by Western blotting. (A) Validation of SUMOylated Drebrin by
FLAG-SUMO1 IP. HEK293 cells were transfected with “FL” SUMO-1 (full length) or
“GG-T95R” SUMO-1 (last four amino acids truncated, with T95R mutation). Forty-eight
hours post-transfection, FLAG-SUMO-1 IP was performed and IP products were
subjected to SDS-PAGE. Western blotting was performed using antibodies against
Drebrin with longer and short exposure time. (B) Validation of SUMOylated Drebrin by
HA-Drebrin IP. HEK293 cells were transfected with FLAG-SUMO-1 (full length) and
HA-Drebrin (WT). Forty-eight hours post-transfection, HA-Drebrin IP was performed
and IP products were subjected to SDS-PAGE. Western blotting was performed using
antibodies against FLAG, HA and actin.

(A)
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(B)
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Figure 2.9. Identification of Drebrin SUMOylation sites by FLAG-SUMO-1 IP and
HA-Drebrin IP. (A) Identification of Drebrin SUMOylation sites by FLAG-SUMO-1 IP.
HEK293 cells were transfected with full length FLAG-SUMO-1 and HA-Drebrin (WT)
or mutant HA-Drebrin including K185R/K186R, K192R, K270R/K271R and K185R
/K186R/ K192R /K270R/K271R (“5-K mutant”). FLAG-SUMO-1 IP was performed and
IP products were subjected to SDS-PAGE. Western blotting was performed using
antibodies against HA, FLAG and actin. (B) Identification of Drebrin SUMOylation sites
by HA-Drebrin IP. HEK293 cells were transfected with full length FLAG-SUMO-1 and
HA-Drebrin (WT) or mutant HA-Drebrin including K185R/K186R, K192R and
K270R/K271R. HA-Drebrin IP was performed and IP products were subjected to SDSPAGE. Western blotting was performed using antibodies against HA, FLAG and actin.
Quantification of SUMOylated Drebrin/Drebrin was done by Image J software. The
relative amount of SUMOylated Drebrin was obtained by normalization of SUMOylated
Drebrin to HA-Drebrin and this number for WT Drebrin was set to 1. All other mutants
were normalized accordingly. The quantification data is shown in red.
(A)
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(B)
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Figure 2.10. Immunostaining of Drebrin and actin filament in CHO cells. CHO cells
were transfected with WT Drebrin or mutant Drebrin (K185R/K186R or K270R/K271R)
or empty HA vector. Non-transfected CHO cells also were used as control cells. Twentyfour hours post-transfection, cells were fixed with 4% PFA and permeabilized with 0.1%
Triton. Primary antibody HA (1:300) or Drebrin (1:50) and secondary antibody Alexa
Fluro 594 (mouse or rabbit) (red, 1:300), as well as DAPI (blue, 1:2000), Oregon Green
488 phalloidin (green, 1:50) were used. Confocal microscopy was applied for observation.
Scale bars=10 µm. (A) Immunostaining of Drebrin and actin. (B) Quantification of % of
protrusions in each sample. The data were presented as mean ± S.D., and one way
ANOVA analysis with Tukey’s test was used to analyze the differences between the
individual experiments.
(A)
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(B)
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Table 2.1. Seventy-four proteins identified in cells expressing four different SUMO1 constructs. Proteins were identified by nano-LC-MS/MS from in-gel tryptic digestion
followed by MASCOT search. The number of SUMOylation consensus sites and
predicted non-consensus SUMOylation sites were analyzed by SUMOsp 2.0 software. A
number of proteins with higher number of predicted SUMOylation sites (large than four,
at least one SUMO consensus site) were highlighted.
Accession

Protein Description

Alpha-actinin-4
Fructose-bisphosphate
ALDOA_HUMAN aldolase A
ATP synthase subunit
alpha,
mitochondrial
ATPA_HUMAN
precursor
ATP synthase subunit
beta,
mitochondrial
ATPB_HUMAN
precursor
C-1-tetrahydrofolate
synthase,
cytoplasmic
C1TC_HUMAN
(C1-THF synthase)
ATP-dependent
RNA
DDX3X_HUMAN helicase DDX3X
Probable ATP-dependent
DDX5_HUMAN
RNA helicase DDX5
Drebrin
(DevelopmentallyDREB_HUMAN
regulated brain protein)

SUMO
consensus sites
1

Non-consensus
sites
3

0

2

1

0

0

1

1

0

1

1

1

2

1

3

0

1

1

1

1

1

1

2

1

1

4

2

0

0

ACTN4_HUMAN

EF1D_HUMAN

GTF2I_HUMAN

Elongation factor 1-delta
Elongation factor 1gamma
Elongation factor Tu,
mitochondrial precursor
Glyceraldehyde-3phosphate
dehydrogenase
Glutathione S-transferase
Mu 2
General
transcription
factor II-I (GTFII-I)

H4_HUMAN

Histone H4

EF1G_HUMAN
EFTU_HUMAN

G3P_HUMAN
GSTM2_HUMAN

Contd.
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IF5A1_HUMAN

Heterogeneous nuclear
ribonucleoprotein
H
(hnRNP H)
Heterogeneous nuclear
ribonucleoproteins
C1/C2
Heterogeneous nuclear
ribonucleoprotein D0
Heterogeneous nuclear
ribonucleoprotein U
Eukaryotic
initiation
factor 4A-I
Eukaryotic
translation
initiation factor 5A-1

IMA2_HUMAN

Importin alpha-2 subunit

IMB1_HUMAN

Importin beta-1 subunit
Ras GTPase-activatinglike protein IQGAP1
ATP-dependent
DNA
helicase 2 subunit 1
DNA
replication
licensing factor MCM3
DNA
replication
licensing factor MCM4
DNA
replication
licensing factor MCM7

HNRH1_HUMAN

HNRPC_HUMAN
HNRPD_HUMAN
HNRPU_HUMAN
IF4A1_HUMAN

IQGA1_HUMAN
KU70_HUMAN
MCM3_HUMAN
MCM4_HUMAN
MCM7_HUMAN
MYH10_HUMAN

NONO_HUMAN

Myosin-10
Myosin light polypeptide
6
H/ACA
ribonucleoprotein
complex subunit 1
Non-POU
domaincontaining
octamerbinding protein

NPM_HUMAN

Nucleophosmin (NPM)

NUCL_HUMAN

Nucleolin (Protein C23)

MYL6_HUMAN

NOLA1_HUMAN

0

2

2

8

1

3

3

5

1

1

0

1

0

2

0

3

4

11

2

4

0

5

1

2

0

4

6

10

0

0

0

0

1

2

2

3

4

4

Contd.
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ODPA_HUMAN
PARP1_HUMAN
PCBP1_HUMAN
PCBP2_HUMAN
PCNA_HUMAN
PLST_HUMAN
PPIA_HUMAN
PRPS1_HUMAN
RAN_HUMAN
RAGP1_HUMAN
RL11_HUMAN
RL14_HUMAN
RL19_HUMAN
RL22_HUMAN
RL24_HUMAN
RL27_HUMAN
RL31_HUMAN
RL38_HUMAN
RL4_HUMAN
RL9_HUMAN
ROA1_HUMAN

Pyruvate dehydrogenase
E1 component alpha
subunit
Poly
[ADP-ribose]
polymerase 1
Poly(rC)-binding protein
1
Poly(rC)-binding protein
2
Proliferating cell nuclear
antigen (PCNA)
Plastin-3 (T-plastin)
Peptidyl-prolyl cis-trans
isomerase A
Ribose-phosphate
pyrophosphokinase I
GTP-binding
nuclear
protein Ran
Ran GTPase-activating
protein 1
60S ribosomal protein
L11
60S ribosomal protein
L14
60S ribosomal protein
L19
60S ribosomal protein
L22
60S ribosomal protein
L24
60S ribosomal protein
L27
60S ribosomal protein
L31
60S ribosomal protein
L38
60S ribosomal protein
L4 (L1)
60S ribosomal protein
L9
Heterogeneous nuclear
ribonucleoprotein A1

0

1

5

11

0

0

0

1

1

0

0

2

1

0

0

0

0

0

2

1

1

1

1

1

1

4

0

0

2

2

1

0

0

0

0

3

0

2

0

1

0

3
Contd.
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RS3A_HUMAN

40S ribosomal protein
S14
40S ribosomal protein
S15a
40S ribosomal protein
S3a

RS4X_HUMAN

40S ribosomal protein S4

RS6_HUMAN

SUMO1_HUMAN

40S ribosomal protein S6
Splicing factor, prolineand glutamine-rich
Spectrin alpha chain,
brain
Spectrin beta chain,
brain 1
Small ubiquitin-related
modifier 1 precursor
(SUMO-1)

TBA3_HUMAN

Tubulin alpha-3 chain

TBB2C_HUMAN

Tubulin beta-2C chain

TBB3_HUMAN

TIF1B_HUMAN

Tubulin beta-3 chain
T-complex protein 1
subunit delta (TCP-1delta)
T-complex protein 1
subunit epsilon
T-complex protein 1
subunit eta
T-complex protein 1
subunit zeta-2
T-complex protein 1
subunit zeta
Transcription
intermediary factor 1beta (TIF1-beta)

XPO2_HUMAN

Exportin-2 (Exp2)

RS14_HUMAN
RS15A_HUMAN

SFPQ_HUMAN
SPTA2_HUMAN
SPTB2_HUMAN

TCPD_HUMAN
TCPE_HUMAN
TCPH_HUMAN
TCPW_HUMAN
TCPZ_HUMAN

74

0

2

0

0

2

0

0

4

0

4

2

1

2

9

3

13

0

0

0

0

0

0

0

0

0

1

1

1

1

3

1

4

2

4

2

1

0

1

Table 2.2. Thirteen proteins with “GG”-tag identified by mass spectrometry from
cells overexpressing SUMO-1 (“GG-T95R”). Proteins were identified by nano-LCMS/MS from in-gel tryptic digestion followed by MASCOT search. T-complex protein 1
subunit delta and Ran GTPase-activating protein 1 are also in the common protein list
(Table 2.1).

ADP-ribosylation factor 1
Cell division cycle 2-related protein kinase 7
C-jun-amino-terminal kinase-interacting protein 4
EH-domain-containing protein 1 (Testilin)
Endothelial zinc finger protein induced by tumor necrosis factor alpha (Zinc finger
protein 71)
Endothelin-1 precursor (Preproendothelin-1) (PPET1)
Lethal(2) giant larvae protein homolog 1 (LLGL)
Microtubule-associated protein 1B (MAP 1B)
Protein Wnt-5b precursor
Ran GTPase-activating protein 1
Synaptonemal complex protein 1 (SCP-1)
T-complex protein 1 subunit delta (TCP-1-delta)
Tyrosine-protein kinase HCK

Copyright © Xiaoyan Liu 2012
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Chapter 3. The role of PDB-associated p62 mutants in NF-κB signaling pathway

Introduction

PDB-associated p62 mutations are in 40% of the familiar PDB cases, and the
upregulation (or defective) NF-κB signaling pathway is linked to PDB [7, 9]. Therefore,
it is important to know the functional consequences of p62 PDB mutations [7, 9].
However, not much of the cellular impact of PDB-associated p62 mutations is known. In
this Chapter, the focus is on the role of p62 PDB mutants in the NF-κB signaling pathway,
which is related to the formation of hyperactivated osteoclasts as described in Chapter 1
[59, 67]. Specifically, we ask two important questions: (1) Do PDB-associated p62
mutations increase the NF-κB signaling? and (2) If so, by which mechanism do p62 PDB
mutants increase the signaling?
Previous studies have reported that four mutations in p62 including P364S [79],
K378X [81], P392L [79, 80] and E396X [81] increased NF-κB signaling. In this Chapter,
whether several other mutants (M404V, G411S, D335E and A381V) also increase the
NF-κB signaling was tested. Also, there is no report regarding how p62 PDB mutants
increase the NF-κB signaling [9, 59]. Therefore, the possible mechanisms by which PDBassociated p62 mutants increase the NF-κB signaling pathway were tested.
We initiated our study on the impact of p62 PDB mutants using Raw264.7 cells,
which are osteoclast-like cells and widely used in the field [170]. To study the impact of
PDB-associated p62 mutants on signaling, NF-κB luciferase assays and IκB degradation
assays were performed in Raw264.7 cells overexpressing WT p62 and mutant p62

76

induced by the GST-rRANKL [171]. Due to the high background of endogenous p62 and
low transfection efficiency of Raw264.7 cells, it was challenging to draw definite
conclusions. TNFα and RANKL belong to the same family [172]. Therefore, we
subsequently studied the impact of p62 PDB mutants in TNFα-induced NF-κB signaling
using p62 KO MEF cells, which have the advantage of lacking of endogenous p62.
Furthermore, previous studies have reported that p62 facilitates TRAF6
polyubiquitination, and activates the NF-κB signaling pathway [94]. Therefore, we firstly
hypothesized that PDB-associated p62 mutants increase NF-κB signaling by increasing
TRAF6 polyubiquitination. In this Chapter, we aim to test this hypothesis.

Materials and methods

Cells and reagents
Raw264.7 cells were a gift from Dr. Lisa Cassis (University of Kentucky). WT
MEF and p62 KO MEF cells were kindly provided by Dr. Masaaki Komatsu at Tokyo
Metropolitan Institute of Medical Science [106]. The Raw264.7 cell line stably
expressing the NF-κB luciferase reporter was generously shared by Dr. Jiake Xu
(University of Western Australia, Australia) [170, 173]. HEK 293 cells stably expressing
RANK receptor was kindly provided by Dr. Sarah Rea (Sir Charles Gairdner Hospital,
Australia) and Dr. Julie Crockett (University of Aberdeen, United Kingdom) [79].
Cells were cultured at 37°C with 5% CO 2. HEK293 cells were cultured in
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), 100 units/ml penicillin and 100 µg/ml streptomycin. WT MEF and p62 KO
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MEF cells were cultured in DMEM supplemented with FBS, PS, 100 mM Sodium
Pyruvate (11360-070; Invitrogen) and 10 mM Non-Essential Amino Acids (11140-050;
Invitrogen). Raw264.7 cells were cultured in DMEM supplemented with FBS, PS,
Sodium Pyruvate (Invitrogen), Non-Essential Amino Acids (Invitrogen) and 20 mM
HEPES (15630-106; Invitrogen). For Raw264.7 cells stably expressing NF-κB luciferase
reporter, an additional 400 µg/ml G418 (G8168; Sigma) was required. HEK293 cells
stably expressing the RANK receptor were cultured in DMEM supplemented with FBS,
PS and 100 µg/ml Hygromycin B (400053; EMD Biosciences).
Additionally, GST-rRANKL, NF-κB luciferase reporter and HA-RANK plasmids
were generous gifts from Dr. Jiake Xu (University of Western Australia, Australia) [171,
173]. GST-rRANKL protein was purified with the help of Dr. Weimin Gong (Institute of
Biophysics in Beijing, China). HA-Ub constructs including K29R, K48R and K63R were
kindly shared by Dr. Marie Wooten (Auburn University). The 3xHA-Ub constructs
including WT, “K48 only” and “K63 only” were gifts from Dr. Matthew Gentry
(University of Kentucky). The phRL-TK (Renilla) vector used in this study was from
Promega. The information of plasmids is summarized in Appendix I.

Plasmid construction
The Myc-p62 (human) plasmid was a gift from Dr. Marie Wooten (Auburn
University). The human p62 was amplified by PCR and was inserted among the EcoRI
and KpnI sites of the p3xFLAG-CMV10 vector (Sigma). Five PDB mutants, including
D335E, A381V, P392L, M404V and G411S were generated by using the QuikChange II
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Site-Directed Mutagenesis Kit (Stratagene). The details of these plasmids (Appendix I)
and designed primers (Appendix II) for mutagenesis are shown in the Appendix.

NF-κB luciferase assay
For the study of RANKL-induced NF-κB signaling, 70% confluent Raw264.7
cells stably expressing NF-κB luciferase reporter were transfected with Renilla control
vector and WT p62 or p62 PDB mutants. Forty-eight hours after the transfection, cells
were treated with GST-rRANKL (30ng/ml) for 7 hours. Cells were lysed with the Passive
Lysis Buffer (PLB) of the Dual Luciferase Reporter Assay System (Promega). Aliquots
of the cell lysates were subjected to SDS-PAGE and Western blotting using antibodies
including

anti-FLAG

(A8592;

Sigma)

and

anti-actin

(sc-1616;

Santa

Cruz

Biotechnology). The NF-κB luciferase assays were performed using the Dual Luciferase
Reporter Assay System (Promega) using Optocomp I luminometer.
For the study of TNFα-induced NF-κB signaling, 70% confluent p62 KO MEF
cells or WT MEF cells were transfected with Renilla vector, NF-κB luciferase reporter
and WT p62 or p62 PDB mutants. Twenty-four hours after the transfection, cells were
starved with DMEM containing only 0.1% BSA for 4 hours. Cells were then treated with
20 ng/ml mouse TNFα (315-01A; PeproTech, Inc.) overnight. The next day, cells were
lysed in PLB. Aliquots of the cell lysates were subjected to SDS-PAGE and Western
blotting using antibodies including anti-FLAG (A8592; Sigma) and anti-actin (sc-1616;
Santa Cruz Biotechnology). NF-κB luciferase assays were performed using the Dual
Luciferase Reporter Assay System (Promega).
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Statistical analysis
Three independent NF-κB luciferase assays in either p62 KO MEF cells or
HEK293 cells were performed. All data were presented as mean with standard deviation
(SD). The significant differences in NF-κB activity fold increases between control cells
and cells expressing WT p62 were analyzed by t-test. The significant differences in NFκB activity fold increases among cells expressing WT p62 and p62 PDB mutant were
analyzed by one-way ANOVA, with Tukey’s post-test using the software GraphPad
Prism 5 Demo.

Monitoring the rate of IκB degradation
Raw264.7 cells or p62 KO MEF cells were transfected with WT p62 or M404V
p62. After 24 hours, the cells were either left untreated or were treated with GSTrRANKL (100 ng/ml) or mouse TNFα (30 ng/ml) for 15 or 45 minutes. Then, the cells
were lysed with RIPA buffer (Millipore) supplemented with PMSF, P8340 protease
inhibitor cocktail (Sigma), Na 3 VO 4 and NEM for 30 minutes. The cell lysates were
centrifuged at 1000g for 10 minutes and the supernatants were boiled with 6xSDS
loading buffer. Samples were subjected to SDS-PAGE, followed by Western blotting
using antibodies including anti-IκBα (mAb #4812; Cell Signaling) and anti-actin (sc1616; Santa Cruz Biotechnology).
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P65 nuclear translocation
Raw264.7 cells were left untreated or treated with GST-rRANKL (100 ng/ml) for
30 minutes. The cells were fixed with 4% paraformaldehyde (PFA) at 37°C for 15
minutes, permeabilized with 0.1% Triton in PBS and blocked with 3% bovine serum
albumin (BSA) in PBS for 1 hour. All the primary and secondary antibodies were diluted
in 3% BSA/PBS. Cells were first stained with p65 antibody (mouse, sc-8008, Santa Cruz
Biotechnology, 1:50) overnight. The next day, the coverslips were washed with PBS and
incubated with Hoechst (33258; Sigma, 1:1000) and secondary Alexa Fluor 488 antimouse antibody (A21202; Invitrogen, 1:300) for 2 hours. Finally, the coverslips were
mounted using Vectashield mounting medium (Vector Laboratories). Fluorescence
microscopy was performed using a confocal microscope (Olympus FluoView) with a 60x
objective.

P62 siRNA
Raw264.7 cells or Raw264.7 cells stably expressing NF-κB luciferase reporter
were transfected with non-targeting siRNA (Dharmacon, D-001210-01-05) or p62 siRNA
(40nM or 80nM, Dharmacon, M-047628-01) using Lipofectamine LTX transfection
reagent (Invitrogen) in the Opti-MEM reduced serum medium (Invitrogen). Forty-eight
hours after transfection, cells were lysed with RIPA buffer (Millipore). The cell lysates
were centrifuged at 1000g for 10 minutes and the supernatants were boiled with 6xSDS
loading buffer. Samples were subjected to SDS-PAGE. The knockdown efficiency was
checked by Western blotting using antibodies including anti-p62 (H00008878-M01;
Abnova) and anti-actin (sc-1616; Santa Cruz Biotechnology).
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TRAF6 ubiquitination assay

HEK293 cells were transfected with FLAG-TRAF6 and DsRed-p62 (WT or
mutant) using the Lipofectamine transfection reagent (Invitrogen). Forty-eight hours after
transfection, cells were lysed using either PPHB buffer (50 mM Na 2 HPO 4 , 1 mM sodium
pyrophosphate, 20 mM NaF, 2 mM EDTA, 2 mM EGTA and 1% Triton X-100) or RIPA
buffer (Millipore). Cells were starved for 3.5 hours and treated with human TNFα
(30ng/ml) for 10 minutes. The cell lysates were centrifuged at 1000g for 10 minutes and
pre-cleared with Sepharose 4L-CB (Sigma) beads for 1 hour. The lysates were then
incubated with anti-FLAG M2 affinity beads for 2 hours at 4°C (F2426; Sigma). The
beads were washed three times with lysis buffer and the immunoprecipitation (IP)
products were eluted by boiling in SDS-PAGE loading buffer. The IP products and the
extracts were subjected to SDS-PAGE using 4–20% ReadyGel Tris–HCl gradient gels
(BioRad), followed by Western blotting with different antibodies including anti-ubiquitin
(sc-8017, Santa Cruz Biotechnology), anti-FLAG (A8592; Sigma) and anti-actin (sc1616, Santa Cruz Biotechnology).

Western blotting and quantification
Nitrocellulose membrane was incubated in blocking solution, 5% milk in TrisBuffered Saline and Tween 20 (TBST) for one hour. Then the membranes were incubated
with primary antibody for more than three hours. After four washes with TBST for five
minutes each, the membrane was incubated with the secondary antibody for more than
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one hour. After four washes again with TBST for five minutes each, proteins of interest
were visualized by either normal or dura enhanced chemiluminescent (ECL) substrate
(Thermo scientific) for detection of horseradish peroxidase (HRP) enzyme (Thermo
scientific). The membrane was covered with the wrapping membrane and an
autoradiography film (Denville Scientific) which was exposed to the membrane. The
exposure time varied from one second to 20 minutes depending on the signal intensity.
Films were subsequently developed by a Kodak X- OMAT 2000 processor.
Software Image J was used for quantification of Western blotting bands on X-ray
films. Since ECL signals of the Western blot were captured on X-ray films which are
known to have a narrow linear range of detection, the quantification of the Western blot
may be out of linear range for certain experiments. Enhanced chemofluorescence (ECF)
substrate and Alkaline Phosphatase (AP)-conjugated secondary antibody are encouraged
for use in the future.

Results
Effect of the p62 PDB mutation on RANKL-induced NF-κB signaling in Raw264.7
cells
We used three classical techniques, including the NF-κB luciferase assay, IκB
degradation assay and p65 nuclear translocation assay, to study the impact of PDBassociated p62 mutants in the RANKL-induced NF-κB signaling.
(1) NF-κB luciferase assay
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The schematic diagram of the NF-κB signaling in these studies is shown in Fig. 3.1.
After RANKL treatment, a significant increase of the luciferase signal was observed,
suggesting that the RANKL reagent and the whole system were working (Fig. 3.2 C). It
was also shown that the endogenous level of p62 was high (Fig. 3.2 A). The level of
overexpressed p62 was different among WT p62 and mutant p62 (M404V, A381V and
P392L) (Fig. 3.2 A). Therefore, it is reasonable to normalize the NF-κB luciferase data
using the expression level of p62 (Fig 3.2 B). The original data of Firefly and Renilla
were shown in Fig. 3.2 C. Fold increases after treatment were calculated by using the
Firefly data divided by the Renilla. These increased ratios were further calibrated by
using the data from the overexpressed p62 without treatment (Fig 3.2 B). Final calibrated
fold increases were obtained (Fig. 3.2 D). It is shown that mutant M404V and A381V
increased the NF-κB luciferase activity compared with WT p62 (Fig. 3.2 D). The high
endogenous p62 level in Raw264.7 cells prevented us from further studying the impact of
mutant p62 on signaling (Fig. 3.2 A). Also, the luciferase assay in HEK293 cells
expressing the RANK receptor induced by RANKL was used, but did not produce a
signal (data not shown).
(2) IκB degradation assay
The IκB degradation assay in Raw264.7 cells induced by RANKL (Fig. 3.3) was
then performed. When stimulated with RANKL, IκB was phosphorylated, ubiquitinated
and degraded by the proteasome (Fig. 1.5). Therefore, the lower IκB level indicates
increased NF-κB signaling activity. The data showed that the IκB level in cells
expressing M404V was always lower than that in cells expressing WT p62 when treated
with RANKL for either 15 or 45 minutes (Fig. 3.3 B). This result indicates that M404V
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p62 increased the NF-κB signaling. Again, due to the high endogenous p62 level in
Raw264.7 cells, it is difficult to reach a definite conclusion.
(3) P65 nuclear translocation
Raw264.7 cells were either treated or untreated with RANKL for 30 minutes. P65
nuclear translocation was observed using confocal microscopy. After stimulation of
RANKL in Raw264.7 cells, a significant amount of p65 was observed in the nucleus (Fig.
3.4 upper panel), whereas p65 remained in the cytoplasm without treatment (Fig. 3.4
lower panel). These results indicate that RANKL induced p65 nuclear translocation.
Since the high background of p62 is an issue, comparison of the WT p62 and mutant p62
has not been done. Also, a better cell model system is needed to study the impact of p62
PDB mutants in RANKL-induced NF-κB signaling (see “Discussion”).
Attempts to knockdown the endogenous level of p62 of Raw264.7 cells by using
the siRNA were also tried. However, the p62 siRNA (40nM and 80nM) did not decrease
the endogenous p62 level (Fig. 3.5). It is possible that Raw264.7 cells have low
transfection efficiency for siRNA too.
P62 contributes to TNFα-induced NF-κB signaling
Firstly, this study has shown that the Firefly/Renilla ratio after TNFα treatment was
higher in WT MEF cells compared with p62 KO MEF cells (Fig. 3.6 A and B). It is
shown that overexpression of WT p62 in p62 KO MEF cells increased the signaling
compared with control p62 KO MEF cells (Fig. 3.6 C and D). Altogether, this suggests
that p62 contributes to TNFα-induced NF-κB signaling.

85

This conclusion is further supported by three independent TNFα-induced NF-κB
luciferase assays in p62 KO MEF cells (Fig. 3.9 A). In order to find the best
concentration of TNFα for measurement, cells were treated with different concentrations
of TNFα (9 ng/ml, 18 ng/ml and 30 ng/ml) overnight. It is shown that 18 ng/ml
performed best which could cause the largest difference of Firefly/Renilla signals
between cells overexpressing WT p62 and control cells (Fig. 3.7). Therefore, 20ng/ml
TNFα for the following luciferase assay for statistical study was used. It is shown that
cells expressing WT p62 had higher fold increases after TNFα treatment compared with
control cells to a statistically significant extent, with the p value 0.034 (Fig 3.9 A).
P62 PDB mutants have a tendency to increase NF-κB signaling compared with WT
p62
Next, the impact of PDB-associated p62 mutants in TNFα-induced NF-κB
signaling was examined. Firstly, it is shown that Firefly/Renilla signals were higher in
p62 KO MEF cells overexpressing M404V p62 compared with WT p62, suggesting that
M404V p62 increased TNFα-induced NF-κB signaling compared with WT p62 (Fig. 3.6
C and D). Then, we performed three independent TNFα-induced NF-κB luciferase
assays in p62 KO MEF cells (Fig. 3.8 and 3.9). The expression level of FLAG-p62 was
similar among cells overexpressing WT and mutant p62 (Fig. 3.8 A). The expression
level of p62 was also used for calibration of fold increases in the analysis (Fig. 3.9 C).
Firefly/Renilla signals with or without TNFα in cells overexpressing WT and
mutant p62 are shown in Fig. 3.8 B. The fold increases were calculated by using
Firefly/Renilla (with TNFα) divided by Firefly/Renilla (without TNFα). The luciferase
data either without considering the p62 expression level (“Non-calibrated fold increases”,
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Fig. 3.9 B) or considering the p62 level (“Calibrated fold increases”, Fig. 3.9 C) was
analyzed. After statistical analysis, it is shown that p62 PDB mutants including M404V,
A381V and P392L all increased signaling compared with WT p62 (Fig. 3.9 B and C).
However, the increase is not statistically significant with the p value larger than 0.05.
The TNFα-induced NF-κB luciferase assay was also performed in HEK293 cells.
The results have shown that p62 PDB mutants had a tendency to increase the signaling
compared with WT p62 (Fig. 3.10 B).

P62 PDB mutant suppresses its binding with polyubiquitinated proteins in HEK293
cells

Next, we considered mechanisms by which p62 PDB mutants increased signaling.
We started to study the cellular consequences of p62 PDB mutants. Because most of PDB
mutations are in the UBA domain of p62, which binds the polyubiquitinated proteins [9],
we want to know that whether these p62 PDB mutants have effects on the binding of
polyubiquitinated proteins.
To address this question, HEK293 cells were transfected with human FLAG-p62
(WT, M404V, A381V, P392L and G411S) or mouse p62 (WT and UBA domain deleted).
Forty-eight hours after transfection, FLAG-IP was performed, and it was shown that all
of the mutants, especially M404V and P392L p62, impaired the binding of p62 and
polyubiquitinated proteins compared with WT p62 (Fig. 3.11). Mouse p62 (UBA domain
deleted) also impaired its binding with polyubiquitinated proteins compared with mouse
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WT p62, suggesting the validation of negative control (Fig. 3.11). However, for the
FLAG-p62 IP shown in Fig. 3.11, whether it was polyubiquitination of p62 or
polyubiquitination of other proteins remains investigation.

Overexpression of p62 in HEK293 cells leads to TRAF6 polyubiquitination in
HEK293 cells

As mentioned above, it was found that the p62 PDB mutations abolish binding with
polyubiquitinated proteins in HEK293 cells. It has also been reported that TRAF6
polyubiquitination is regulated by p62 [94]. Therefore, it is possible that p62 PDB
mutations could have effects on TRAF6 polyubiquitination. To address this question, the
TRAF6 ubiquitination assay in HEK293 cells overexpressing FLAG-TRAF6 and DsRedp62 (WT, M404V, A381V and P392L) was performed.
It is shown that in the basal condition, the level of TRAF6 polyubiquitination in
cells overexpressing WT p62 is much higher than control cells, indicating that
overexpression of p62 in HEK293 cells leads to TRAF6 polyubiquitination (Fig. 3.12,
3.13 and 3.14). In addition, it was found that the level of TRAF6 polyubiquitination
increases in proportion to the amount of p62 (Fig. 3.13). It is indicated that the level of
TRAF6 polyubiquitination is dependent on p62 amount.

Mutant p62 impaired TRAF6 polyubiquitination compared with WT p62 in
HEK293 cells

From the TRAF6 ubiquitination assay in HEK293 cells above, it was shown that
the level of TRAF6 polyubiquitination in cells overexpressing PDB-associated p62
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mutants (M404V, A381V and P392L), especially M404V p62 is lower than cells
overexpressing WT p62 (Fig. 3.12, 3.13 and 3.14). Therefore, p62 PDB mutants,
especially M404V, impaired TRAF6 polyubiquitination compared with WT p62 in the
basal condition. However, compared with control cells without overexpression of p62,
cells overexpressing p62 PDB mutant still increase TRAF6 polyubiquitination (Fig. 3.12,
3.13 and 3.14), indicating that both the WT and the p62 PDB mutant could facilitate
TRAF6 polyubiquitination in HEK293 cells.
TNFα did not induce TRAF6 polyubiquitination in HEK293 cells

As mentioned above, it was shown that p62 contributes to TNFα-induced NF-κB
signaling (Fig. 3.9 A). It was also shown that PDB-associated p62 mutants increased
TNFα-induced NF-κB signaling (Fig. 3.9 and 3.10). Furthermore, it is shown that both
WT and mutant p62 facilitate TRAF6 polyubiquitination in HEK293 cells in the basal
condition (Fig. 3.12, 3.13 and 3.14). Therefore, it was of interest to determine whether
WT p62 and p62 PDB mutants change TRAF6 polyubiquitination upon TNFα treatment
compared with basal conditions. In order to address this question, TRAF6 ubiquitination
assay was performed in the absence and presence of TNFα in HEK293 cells. It was
shown that TNFα was effective because IκB was degraded after TNFα treatment (Fig
3.14). However, the change of TRAF6 polyubiquitination after TNFα treatment (Fig.
3.14) was not observed. Therefore, it is suggested TNFα does not play a role on TRAF6
polyubiquitination in HEK293 cells.
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Overexpression of p62 in HEK293 cells leads to a TRAF6 polyubiquitination chain
of different linkages

Previous work has shown that p62 facilitates K63-linked polyubiquitination of
TRAF6 and further activates the NF-κB signaling [95] (Fig. 1.5). In this study, it was
found that p62 facilitates TRAF6 polyubiquitination in HEK293 cells. Therefore, is the
TRAF6 polyubiquitination observed (Fig. 3.12 and Fig. 3.14) a K63-linked chain? Could
the TRAF6 polyubiquitination observed activate the NF-κB signaling upon TNFα
treatment?
To address these questions, HEK293 cells were transfected with FLAG-TRAF6,
DsRed-p62 (WT) and a variety of different HA-Ub constructs including K29R, K48R,
K63R [95], as well as “K48 only” or “K63 only” in which all the Lys of Ub are mutated
to Arg except Lys48 or Lys63, respectively. If it is a K63-linked chain, the level of
TRAF6 polyubiquitination should decrease in cells overexpressing HA-Ub (K63R)
compared with cells overexpressing WT Ub. However, this difference (Fig. 3.15, lane 1
and 4) was not seen. There is no difference among levels of TRAF6 polyubiquitination in
cells overexpressing K29R Ub, K48R Ub and K63R Ub (Fig. 3.15, lane 2-4). In addition,
there is no difference between levels of TRAF6 polyubiquitination in cells
overexpressing Ub (“K63 only”) and Ub (“K48 only”) (Fig. 3.15, lane 5 and 6).
Altogether, it is suggested that the TRAF6 polyubiquitination observed is not a K63linked chain, but a mixture of K48-linked, K63-linked and K29-linked chains.
Moreover, from the TRAF6 polyubiquitination assay in HEK293 cells with and
without TNFα treatment (Fig. 3.14), it is shown that overexpression of p62 could not
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activate the NF-κB signaling because IκB level is similar in the absence and presence of
p62 (Fig. 3.14). Therefore, the TRAF6 polyubiquitination observed by overexpressing
p62 in HEK293 cells could not activate the NF-κB signaling (Fig. 3.14).

Discussion
Does p62 really facilitate TRAF6 to form a K63-linked polyubiquitin chain which
activates NF-κB signaling?

Wooten et al. [95] and Moscat et al. [93] have shown that p62 could activate the
NF-κB signaling in HEK293 cells in the basal condition. Our study not only showed that
p62 activates NF-κB signaling basally (Fig. 3.6 C), but also upon TNFα treatment to a
statistically significant degree in p62 KO MEF cells (Fig. 3.9 A) and HEK293 cells (Fig.
3.10 A).
Wooten et al. [95] have reported that the loss of p62 completely abolishes
ubiquitination of TRAF6 by performing TRAF6 immunoprecipitation from lysates of the
brains from p62 WT or knock-out mice. In this study, it was shown that p62 facilitates
TRAF6 polyubiquitination in HEK293 cells (Fig. 3.12 and 3.14). In their study, they have
shown that the TRAF6 polyubiquitination chain is a K63-linked chain by using a variety
of different Ub constructs. We also used these different Ub mutants and performed the
TRAF6 ubiquitination assay as done previously [95]. However, it was found that the
TRAF6 polyubiquitination chain is not K63-linked, but a mixture of K29-linked, K48linked and K63 linked. It was further confirmed by using two other different Ub mutants,
“K48 only” and “K63 only”. The contradictory results between this study and Dr.
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Wooten’s study might be due to the specific experiment details. In their study, although
they have shown that TRAF6 polyubiquitination is a K63-linked chain, they did not show
that this chain is sufficient to induce the NF-κB signaling. In this work, it was shown that
the TRAF6 polyubiquitination observed is not sufficient to induce NF-κB signaling by
comparing the IκB level in cells with and without overexpressing p62 (Fig. 3.14).
These data have shown that p62 contributes to NF-κB activation (Fig. 3.9 A).
However, for the TRAF6 polyubiquitination assay, the IκB level remains similar in
HEK293 cells with and without overexpressing p62, which seems to contradict that p62
contributes to NF-κB signaling. To clarify this point in the future, more signaling proteins
such as IKK and phospho-IκB need to be examined.

Do p62 PDB mutants impair the TRAF6 polyubiquitination upon cytokine
treatment?

In this Chapter, it was shown that M404V p62 impairs TRAF6 polyubiquitination
compared with WT p62 in the basal condition (Fig. 3.12 and 3.14). Also, it has been
shown that M404V p62 had a tendency to increase TNFα-induced NF-κB signaling (Fig.
3.10 B). Because TRAF6 polyubiquitination facilitates NF-κB signaling [125], these two
pieces of data seem to be contradictory. However, it is suggested in the literature that, it
is “K63 linked” polyubiquitination that facilitates NF-κB signaling. Was the “K63
linked” polyubiquitination chain in our FLAG-TRAF6 IP observed? Actually it did not.
These data have shown that the TRAF6 polyubiquitination chain is a mixture of
polyubiquitination chains which contain K29 linked, K48 linked and K63 linked chains
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(Fig. 3.15). Therefore, overexpression of p62 could not facilitate TRAF6 to form the
K63-linked chain.
In addition, overexpression of p62 does not appear to activate NF-κB signaling
because the IκB levels were similar in the absence and presence of p62 (Fig. 3.14). It is
suggested that TRAF6 K63-linked polyubiquitination might require the stimulation of
cytokines, such as TNFα or RANKL. It has also been shown that TNFα did not induce
the TRAF6 polyubiquitination (Fig. 3.14). Therefore, it is indicated that TRAF6 K63linked polyubiquitination could be observed by stimulation with other cytokines, such as
RANKL.
Moreover,

these

data

showed

that

TNFα

did

not

increase

TRAF6

polyubiquitination (Fig. 3.14). Previous studies reported that TNFα increased TRAF2
polyubiquitination [23, 93, 135], but they did not test whether TNFα increased TRAF6
polyubiquitination. Thus, our study expands the knowledge of TNFα. In addition,
Fuanakoshi-Tago et al. [174] have reported that TRAF6 negatively regulates TNFαinduced NF-κB signaling. They found that IKK activation and IκB degradation were
enhanced in TRAF6-deficient MEFs compared with WT MEFs [174]. Although our data
and their data are not directly related, all these studies showed at least that TNFα-induced
NF-κB signaling is not activated through TRAF6.

Three workable cell models for studying the impact of PDB-associated p62 mutants
on NF-κB signaling

(1) Raw264.7 cells
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Previously, Raw264.7 cells stably expressing the NF-κB luciferase reporter were
used as a cell model to study the effect of the p62 on the RANKL-induced NF-κB
signaling. It was thought that Raw cells constituted a good cell model because they are
osteoclast-like cells [170], which are widely used in the field studying PDB. However,
for this project, the goal was to examine the effect of PDB-associated p62 mutations on
NF-κB signaling. Because all these p62 mutations are single point mutations, it was
recognized that it is very important to rule out the effect of the endogenous p62 of Raw
cells. It turned out that Raw cells have a high background of endogenous p62 (Fig. 3.2 A),
whereas the transfection efficiency for Raw cells are also low. The use of p62 siRNA to
knockdown the endogenous p62 of Raw cells was attempted, but p62 siRNA did not
work; this might also be due to the low transfection efficiency of Raw cells (Fig. 3.5).
Therefore, other cell models to study the signaling were considered.
(2) p62 KO MEF cells
P62 KO MEF cells shared by Dr. Masaaki Komatsu (Japan) [106] were used for
this study. The advantage of p62 KO MEF cells is that there is no endogenous p62 in this
cell line. Therefore, it is advantageous to compare the effect of WT p62 and p62 PDB
mutant using this p62 KO MEF cell line. The disadvantage of this cell line is that the
transfection efficiency for the cell is also low. In addition, p62 KO MEF cells did not
respond to the RANKL (data not shown). HA-RANK receptor (shared by Dr. Jiake Xu,
Australia) was transfected into p62 KO MEF cells, and these cells again did not respond
to RANKL (data not shown). However, p62 KO MEF cells did respond to TNFα (Fig.
3.6). Therefore, the study shifted to the effect of PDB-associated p62 mutations on
TNFα-induced NF-κB signaling. The TNFα-induced NF-κB luciferase assay was
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performed in p62 KO MEF cells overexpressing either WT p62 or p62 PDB mutant for
more than three times (Fig. 3.8 and 3.9). These data have shown a tendency for mutant
p62 to increase TNFα-induced NF-κB signaling compared with WT p62, which is not
statistically significant in p62 KO MEF cells. Additionally, it is shown that even without
p62, there is still basal TNFα-induced NF-κB signaling (Fig. 3.9). Also, p62 increases the
TNFα-induced NF-κB signaling pathway to a statistically significant degree (p<0.05)
(Fig. 3.9 A). Therefore, p62 PDB mutants increase NF-κB signaling in p62 KO MEF
cells, but the increase is so subtle that it is difficult to detect with NF-κB luciferase assay.
(3) HEK293 cells
In addition, the TNFα-induced NF-κB assay in HEK293 cells was studied.
HEK293 cells could also respond to TNFα signals (Fig. 3.10). In addition, the increased
folds in cells expressing p62 (the number is over 50) are much higher than control cells,
suggesting that it might be a good model to compare the effect of WT p62 and mutant
p62 on TNFα-induced NF-κB signaling.
It appears to be challenging to study the RANKL-induced NF-κB signaling in this
study. An ideal cell model should have little background of endogenous p62, high
transfection efficiency and response after stimuli of RANKL. While it is difficult to find
such a perfect cell model for study, some ways to optimize our existent cell lines are
considered. The strategies are described below and summarized in Table 3.1.
(1) HEK293 cells stably expressing RANK receptor
Rea el al. [79] reported that P364S and P392L increased RANKL-induced NF-κB
signaling by NF-κB luciferase assay in HEK293 cells stably expressing RANK receptor.
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We also obtained the above stable HEK293 cells from them. Although we tried the same
assay as described in their paper, the NF-κB signaling induced by GST-rRANKL [171]
was not detected (data not shown).
(2) p62 KO MEF cells stably expressing HA-RANK receptor
HA-RANK receptor was also kindly shared by Dr. Jiake Xu (Australia). We also
tried transient transfection of HA-RANK into p62 KO MEF cells, but again cells did not
respond to GST-rRANKL [171] (data not shown). Because currently no report regarding
using p62 KO MEF cells expressing HA-RANK receptor, there is a need to change the
parameters for experiment optimization. If it works in the future, this approach might
generate the p62 KO MEF cells stably expressing HA-RANK receptor.
(3) Raw264.7 cells with p62 shRNA
Since Raw264.7 cells have low transfection efficiency, lentivirus-delivered p62
shRNA and exogenous p62 (WT or mutant) could be applied. It will be necessary to be
careful about the design of p62 shRNA, which should only interfere with endogenous p62,
not exogenous p62. Biosafety issues also need to be considered.

Significance of this study and future directions
The significance of this study in this Chapter is that this is the first example using
the p62 KO MEF cells as a model for studying the effect of p62 PDB mutants on NF-κB
signaling. Also, this is the first study to show that p62 not only increases TNFα-induced
NF-κB signaling basally, but also upon TNFα treatments in p62 KO MEF cells, which
was not reported. Moreover, these data have shown that several PDB-associated p62
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mutants had tendency to increase TNFα-induced NF-κB signaling, which was not
reported before. Additionally, it excluded the possibility that these p62 PDB mutants
increase signaling through increasing TRAF6 polyubiquitination, suggesting the
existence of other mechanisms.
Future directions include examining other possible mechanisms by which p62
PDB mutants increase TNFα-induced NF-κB signaling. Another direction is to find a
better model to study the impact of PDB-associated p62 mutants on RANKL-induced
NF-κB signaling (see Chapter 5). Additionally, previous studies have shown that p62
interacts with RIP and is involved in the TRAF2 polyubiquitination [93] in the TNFαinduced NF-κB signaling, which raises the possibility that PDB-associated p62 mutations
increase TNFα-induced NF-κB signaling through increasing TRAF2 polyubiquitination.
This hypothesis could be investigated in the future.
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Figure 3.1. A schematic diagram of NF-κB luciferase assay.
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Figure 3.2. RANKL-induced NF-κB luciferase assay in Raw264.7 cells expressing
WT p62 and p62 PDB mutants. Raw264.7 cells stably expressing NF-κB luciferase
reporter were transfected with FLAG-p62 (WT, M404V, A381V and P392L) and Renilla.
Forty-eight hours after transfection, cells were treated with GST-rRANKL (100ng/ml) for
7 hours. Cells were harvested with passive lysis buffer and NF-κB luciferase assay was
performed. Cell lysates were also subjected to SDS-PAGE and Western blotting was
performed using antibodies against FLAG and actin. (A) Western blotting of
overexpressed p62 and endogenous p62. (B) Quantification of FLAG-p62/Actin by
Image J. (C) Original Firefly/Renilla ratio with or without RANKL treatment. (D)
Normalized fold increases after RANKL treatment according to the expression level of
p62.

(A)
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(B)

(C)

(D)
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Figure 3.3. Comparison of the rate of IκB degradation in Raw264.7 cells expressing
WT and mutant p62 induced by GST-rRANKL. (A) IκB degradation in Raw264.7
cells overexpressing WT or M404V p62 induced by RANKL at 10 or 45 minutes. (B)
Quantification of IκB/Actin by Image J software.

(A)

(B)
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Figure 3.4. Immunostaining of p65 in Raw264.7 cells induced by GST-rRANKL.
Raw 264.7 cells were treated with and without GST-rRANKL (100ng/ml) for 30 minutes.
Cells were fixed with 4% PFA and permeabilized with 0.1% Triton. Primary antibody
p65 (1:50), secondary antibody Alexa Fluro 488 (mouse) (green, 1:300) and Hoechst
(blue, 1:1000) were used. Confocal microscopy was applied for observation. Scale
bars=5µm.
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Figure 3.5. Knockdown of the endogenous p62 in Raw264.7 cells by p62 siRNA.
Raw264.7 cells stably expressing NF-κB luciferase reporter were transfected with nontargeting siRNA or p62 siRNA (40nM, 80nM) using the Lipofectamine LTX. Forty-eight
hours after transfection, cells were lysed with RIPA buffer. Samples were subjected to
SDS-PAGE. The knockdown efficiency was checked by Western blotting using
antibodies against p62 and actin.
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Figure 3.6. TNFα-induced NF-κB luciferase assays in WT MEF and p62 KO MEF
cells. (A) Firefly/Renilla ratio induced by TNFα in MEF cells. MEF cells were
transfected with NF-κB luciferase reporter and Renilla. Cells were treated with TNFα
(30ng/ml) for 7 hours. (B) Fold increases after TNFα treatment in p62 KO MEF and WT
MEF cells. (C) Firefly/Renilla ratio at basal condition. MEF cells were transfected with
FLAG-p62 (WT or M404V), NF-κB luciferase reporter and Renilla. (D) Firefly/Renilla
ratio with or without TNFα treatment. Cells were treated with TNFα (30ng/ml) for 7
hours.
(A)

(B)
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(C)

(D)
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Figure 3.7. NF-κB luciferase assay induced by different concentration of TNFα in
p62 KO MEF cells. (A) The Firefly/Rellina ratio was obtained at different concentration
of TNFα (9ng/ml, 18ng/ml and 30ng/ml). The cells were starved with DMEM (0.1%
BSA) for 4 hours, and then treated with TNFα overnight. (B) Fold increases by different
concentration of TNFα.
(A)

(B)
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Figure 3.8. TNFα-induced NF-κB luciferase assay in p62 KO MEF cells expressing
WT p62 or p62 PDB mutants. P62 KO MEF cells were transfected with FLAG-p62
(WT, M404V, A381V and P392L), NF-κB luciferase reporter and Renilla. Twenty-eight
hours after transfection, cells were starved for 3.5 hours. Cells were treated with TNFα
(20ng/ml) overnight. Cells were harvested with passive lysis buffer and NF-κB luciferase
assay was performed. Cell lysates were also subjected to SDS-PAGE and Western
blotting was performed using antibodies against FLAG and actin. Three independent
experiments were performed. (A) Representative Western blotting of overexpressed p62
and quantification of FLAG-p62/Actin by Image J. (B) Representative Firefly/Renilla
with and without TNFα.

(A)
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(B)

108

Figure 3.9. Statistical analysis of fold increases in the TNFα-induced NF-κB
luciferase assay in p62 KO MEF cells. TNFα-induced NF-κB luciferase assay were
performed three times. (A) Fold increases of Firefly/Renilla in control cells and cells
expressing WT p62. The data were presented as mean ± S.D., and t-test was used to
analyze the differences between the individual experiments. *: P < 0.05. (B) Fold
increases of Firefly/Renilla in cells expressing WT p62 or p62 PDB mutant. The data
were presented as mean ± S.D., and one way ANOVA analysis with Tukey’s test was used
to analyze the differences between the individual experiments. (C) Fold increases of
Firefly/Renilla in cells expressing WT p62 or p62 PDB mutant were calibrated according
to the expression level of WT or mutant p62. The data were presented as mean ± S.D.,
and one way ANOVA analysis with Tukey’s test was used to analyze the differences
between the individual experiments.
(A)
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(B)

(C)
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Figure 3.10. Statistical analysis of fold increases in the TNFα-induced NF-κB
luciferase assay in HEK293 cells. TNFα-induced NF-κB luciferase assay were
performed three times. HEK293 cells were transfected with FLAG-p62 (WT, M404V,
A381V and P392L), NF-κB luciferase reporter and Renilla. Thirty hours after
transfection, cells were starved overnight. Cells were treated with TNFα (30ng/ml) for 4
hours. (A) Fold increases of Firefly/Renilla in control cells and cells expressing WT p62.
The data were presented as mean ± S.D., and t-test was used to analyze the differences
between the individual experiments. *: P < 0.05. (B) Fold increases of Firefly/Renilla in
cells expressing WT p62 or p62 PDB mutant. The data were presented as mean ± S.D.,
and one way ANOVA analysis with Tukey’s test was used to analyze the differences
between the individual experiments. *: P < 0.05.
(A)
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(B)
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Figure 3.11. Comparison of immunoprecipitated polyubiquitinated proteins in
HEK293 cells overexpressing WT and mutant p62. HEK293 cells were transfected
with FLAG-TRAF6 (WT, A381V, P392L and M404V). Forty-eight hours after
transfection, FLAG-IP was performed. Samples were subjected to 4–20% gradient gels.
Western blotting was performed using antibody against Ub.
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Figure 3.12. Comparison of TRAF6 polyubiquitination in HEK293 cells
overexpressing WT and mutant p62. HEK293cells were co-transfected with FLAGTRAF6 and DsRed-p62 (WT, A381V, P392L or M404V). Forty-eight hours after
transfection, FLAG-IP was performed. Samples were subjected to 4–20% gradient gels.
Western blotting was performed using antibodies against Ub, FLAG and actin.
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Figure 3.13. Comparison of the level of TRAF6 polyubiquitination in HEK293 cells
overexpressing different amount of p62. HEK293 cells were co-transfected with
FLAG-TRAF6 and different amounts (0.5µg, 0.25 µg and 0.1 µg) of DsRed-p62 (WT or
M404V). Forty-eight hours after transfection, FLAG-IP was performed. Samples were
subjected to 4–20% gradient gels. Western blotting was performed using antibodies
against Ub and FLAG.
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Figure 3.14. Comparison of TRAF6 polyubiquitination in HEK293 cells
overexpressing WT and mutant p62 with and without TNFα treatment. HEK293
cells were co-transfected with FLAG-TRAF6 and DsRed-p62 (WT, M404V, A381V or
P392L). Forty-eight hours after transfection, FLAG-IP was performed. Samples were
subjected to 4–20% gradient gels. Western blotting was performed using antibodies
against Ub, FLAG, IκB and actin.
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Figure 3.15. Comparison of TRAF6 polyubiquitination in HEK293 cells
overexpressing p62 and a variety of different ubiquitin constructs. HEK293 cells
were co-transfected with FLAG-TRAF6, DsRed-p62 (WT) and different HA-Ub
constructs including K29R, K48R, K63R, K48 only and K63 only. Forty-eight hours after
transfection, FLAG-IP was performed. Samples were subjected to 4–20% gradient gels.
Western blotting was performed using antibodies against Ub, FLAG, DsRed and HA.

117

Table 3.1. Comparison of three workable cell models for our study.

Copyright © Xiaoyan Liu 2012
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Chapter 4. The role of PDB-associated p62 mutants in autophagy
Introduction
It was reported that the p62 levels were elevated in PDB patients, suggesting a
defect in autophagy [80, 175], which may play a role in the disease [7, 9]. Little is known,
however, about the role of autophagy in PDB. As mentioned earlier, p62 mutations are
linked to about 40% familiar PDB cases. Therefore, the effect of PDB-associated p62
mutations in autophagy was investigated in our study.
There are two important questions regarding the role of p62 in PDB. (1) P62 is a
regulator of autophagy [6, 90] , therefore do p62 PDB mutants increase or decrease
autophagic activity compared with WT p62? and (2) P62 is also a substrate of autophagy
[82, 150], therefore does the rate of autophagic degradation of p62 PDB mutant increase
or decrease compared with WT p62?
In this Chapter, we mainly try to address the first question. We compared the effect
of WT p62 and p62 PDB mutants on the interaction of LC3, a marker for autophagosome.
Then, we also compared the GFP-LC3 puncta among cells overexpressing WT p62 and
mutant p62. In addition, we compared the LC3-II levels after rapamycin (autophagy
inducer) and/or NH 4 Cl (autophagy inhibitor) treatment in cells expressing WT p62 and
mutant p62.
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Methods and materials

Cells and reagents
P62 KO MEF cells were a gift from Dr. Masaaki Komatsu at Tokyo Metropolitan
Institute of Medical Science [106]. Both rapamycin (autophagy inducer, R0395; Sigma)
and NH 4 Cl (autophagy inhibitor, 254134-25G; Sigma) were used in this study.

Plasmids construction
The human p62 open reading frame was amplified by PCR and was inserted among
the EcoRI and KpnI sites of the p3xFLAG-CMV10 vector (Sigma). Five PDB mutants,
including D335E, A381V, P392L, M404V and G411S were generated by site-directed
mutagenesis (in Chapter 3). In addition, the FLAG-p62 (WT, A381V, P392L and
M404V) was inserted between the EcoRI and KpnI sites of the pDsRed monomer C1,
generating four human DsRed-p62 (WT, A381V, P392L and M404V). The mutagenic
primer sequences of these DsRed-p62 constructs are listed in Appendix II.

Immunoprecipitation
HEK293 cells were co-transfected with FLAG-p62 (WT, M404V, A381V and
P392L) and EGFP-LC3 using the Lipofectamine reagent (Invitrogen). After 48 hours, the
cells were lysed with the RIPA buffer with the PMSF (Sigma), P8340 (Sigma), Na 3 VO 4
and NEM for 30 minutes. The cell lysates were centrifuged at 1000g for 10 minutes.
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Then 1000 μg cell lysates were pre-cleared with the Sepharose 4L-CB beads for 1 hour
and subsequently incubated with anti-FLAG M2 affinity beads (F2426; Sigma). The
beads were washed with RIPA buffer and resuspended in SDS loading buffer. The IP
products and the extracts were subjected to SDS-PAGE followed by Western blotting
with antibodies including anti-LC3 (PM036; MBL), anti-FLAG (A8592; Sigma) and
anti-actin (sc-1616; Santa Cruz Biotechnology).

Immunofluorescence and confocal microscopy
P62 KO MEF cells were transfected with FLAG-p62 (WT or M404V) and EGFPLC3. Twenty-four hours after transfection, the cells were fixed with 4%
paraformaldehyde (PFA) at 37 °C for 15 minutes, permeabilized with PBS/0.1% Triton,
and blocked with 3% bovine serum albumin (BSA) in PBS for 1 hour. All the primary
and secondary antibodies were diluted in 3% BSA/PBS. Cells were firstly incubated with
anti-FLAG primary antibody (mouse, F3165; Sigma, 1:230) overnight. The next day, the
cells on the coverslips were incubated with Hoechst (33258; Sigma, 1:1000) and Alexa
Fluor 488 anti-mouse (A21202; Invitrogen, 1:300) for 2 hours. Finally, the coverslips
were mounted using Vectashield mounting medium (Vector Laboratories). Confocal
microscope (Olympus FluoView) was applied with a 60X objective.

Fractionation
P62 KO MEF cells were transfected with FLAG-p62 (WT or M404V) using the
Lipofectamine LTX (Invitrogen). The cells were treated with NH 4 Cl (10mM, 16 hours)
or rapamycin (200nM, 16 hours). Forty-eight hours after transfection, the cells were
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harvested with RIPA buffer with PMSF (Sigma), P8340 (Sigma), Na 3 VO 4 and NEM for
30 minutes. The cell lysates were centrifuged at 1000g for 10minutes and the supernatant
(S1) was collected. S1 was further centrifuged at 20,000g for 50 minutes, generating
supernatant (S2) and pellet (P2). The samples were added to the 6xSDS loading buffer
and subjected to the SDS-PAGE, followed by Western blotting using antibodies
including anti-LC3 (PM036; MBL), anti-FLAG (A8592; Sigma) and anti-actin (sc-1616;
Santa Cruz Biotechnology).

Results
Effect of the p62 PDB mutation on interaction with LC3

LC3-II is an active marker of the autophagosome [8], and p62 binds to LC3
through the LIR domain of p62 [83]. The effect of PDB-associated p62 mutation on this
interaction was tested in this study. HEK293 cells were co-transfected with FLAG-p62
(WT, A381V, P392L and M404V) and EGFP-LC3. FLAG-IP was performed followed by
SDS-PAGE and Western blotting. We used mouse LIR domain deleted p62 as a negative
control, and as expected, it showed no interaction with GFP-LC3 (Fig. 4.1 A, lane 5). The
p62 PDB mutation did not, however, change the interaction with LC3 (Fig. 4.1). The
interaction of LC3 and p62 bearing a mutation (D335E) in LIR domain was also tested.
Interestingly, this mutation also did not alter the interaction with LC3 (data not shown).

Effect of the p62 PDB mutation on GFP-LC3 puncta formation
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In Chapter 3, we showed that M404V p62 impaired TRAF6 polyubiquitination
compared with WT p62 in HEK293 cells (Fig. 3.12 and 3.14). Therefore, we chose this
mutant for the study. P62 KO MEF cells were transfected with FLAG-p62 (WT or
M404V) and EGFP-LC3. After 24 hours, the cells were fixed with 4% PFA and
incubated with anti-FLAG antibody (1:230) and Hoechst (1:1000). Confocal microscopy
was used to observe the GFP-LC3 puncta.
It was found that WT FLAG-p62 colocalized with GFP-LC3 (Fig. 4.2), which is
consistent with reports in the literature [89]. The same colocalization was found for GFPLC3 and M404V p62 (Fig. 4.2). In addition, it was found that p62 and LC3 were
exclusively located in the cytosol (Fig. 4.2). For quantification, nine Z-stack pictures for
each sample were taken (data not shown). Attempts were made to count and compare the
GFP-LC3 puncta in cells overexpressing WT and M404V p62 using available software.
However, a larger number of cells and better software are needed for more precise
quantification.
In the Fig. 4.2, it is shown that GFP-LC3 was in the nucleus. The nuclear staining
of GFP-LC3 is likely due to high levels of overexpression.

Effect of the p62 PDB mutant on LC3-II levels after rapamycin and NH4Cl
treatment

In Chapter 1, I introduced several available autophagy inducers and inhibitors.
Here, we used rapamycin, which inhibits the mTOR pathway, and activates autophagy.
Also we used NH 4 Cl to inhibit the fusion of lysosomes and autophagosomes, thus
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inhibiting autophagy (Fig. 1.7). The level of LC3-II was monitored after treatment with
these compounds.
P62 KO MEF cells were transfected with FLAG-p62 (WT or M404V). Cells were
then treated with rapamycin for 16 hours. Alternatively, cells were treated with
rapamycin and NH 4 Cl together for 16 hours. Forty-eight hours after transfection, cells
were lysed with RIPA buffer. Cell lysates were centrifuged at 1000g for 10 minutes. The
supernatant (S1) was further centrifuged 20,000g for 50 minutes, generating supernatant
(S2) and pellet (P2). The S1, S2 and P2 were subjected to SDS-PAGE followed by
Western blotting.
Since rapamycin is an autophagy inducer, we expected to see LC3-II levels to
increase after rapamycin treatment as more autophagosomes form. For cells without
transfection (NT), LC3-II did increase slightly in S1 and S2, and decreased slightly in P2
after rapamycin treatment (Fig. 4.3 A, lane 1 and 5). For cells transfected with empty
vector or FLAG-p62 (WT or M404V), LC3-II remained similar in S1, and slightly
decreased in S2 and P2 (Fig. 4.3 A, lane 2-4 and lane 6-8). Since LC3-II decreased in P2
after rapamycin treatment in the control cells (Fig. 4.3 A, lane 2 and 6), it was indicated
that rapamycin not only increased the formation of autophagosome, but also increased the
enzymatic activity in the autophagolysosome, therefore more LC3-II was degraded.
Based on Western blotting (Fig. 4.3 A), we quantified the LC3-II/Actin in S1 from cells
overexpressing WT p62 or M404V p62 with and without rapamycin (Fig. 4.3 B). There
was no significant difference between WT p62 and M404V p62 in terms of the change of
LC3-II levels after rapamycin. LC3-II decreased after rapamycin in cells transfected with
empty FLAG (Fig. 4.3 B), suggesting that rapamycin increased the enzymatic activity in
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the autophagolysosome, thereby degrading LC3-II more rapidly. In cells overexpressing
WT p62, the LC3-II levels decreased less compared with the control (7.9% vs. 23.2%)
(Fig. 4.3 B), suggesting that WT p62 attenuated the autophagic activity and the rate of
LC3-II degradation in the autophagolysosome. However, in cells overexpressing M404V
p62, the LC3-II levels decreased more compared with cells overexpressing WT p62
(18.3% vs. 7.9%), suggesting that PDB mutant p62 (M404V p62) may increase the
autophagic activity compared with WT p62 because LC3-II was degraded at a faster rate.
NH 4 Cl decreases autophagy by inhibiting the fusion of lysosomes and
autophagosomes. We expected, therefore, to see LC3-II levels increase after NH 4 Cl
treatment. As expected, LC3-II increased dramatically in S1, S2 and P2 after NH 4 Cl
treatment alone (data not shown). Rapamycin was applied with NH 4 Cl together with the
expectation that this double treatment would raise LC3-II levels even further. Treatment
with both compounds (Fig. 4.3 A, lane 9-12), however, did not further increase LC3-II,
suggesting LC3-II reached maximal levels after treatment with NH 4 Cl alone (data not
shown). Based on the Western blotting (Fig. 4.3 A), we quantified the LC3-II/Actin in S1
from cells overexpressing WT p62 or M404V p62 with and without NH 4 Cl and
rapamycin together (Fig. 4.3 C). It is shown that after double treatment, LC3-II levels in
cells overexpressing WT p62 were higher than control (Fig. 4.3 C), suggesting that p62
may facilitate the autophagic activity, which appears contradictory with Fig. 4.3 B. Also,
it was shown that after double treatment, LC3-II levels in cells overexpressing M404V
p62 were higher than those in cells overexpressing WT p62, suggesting that M404V p62
may increase autophagic activity, which is consistent with Fig 4.3 B. However, since
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LC3-II reached maximal capacity after treatment with NH 4 Cl, a solid conclusion
regarding the impact of p62 PDB mutant on autophagy remains unclear.

Discussion

Challenges of current methods for studying the effect of PDB-associated p62
mutants on autophagy

In this Chapter, we mainly used p62 KO MEF cells to study the effect of PDBassociated mutants on autophagy. We used two common methods for the study. One is
comparing the GFP-LC3 puncta in cells overexpressing WT or mutant p62, the other is
comparing the LC3-II levels in cells overexpressing WT or mutant p62 after treatment
with an autophagy inducer and/or inhibitor.
P62 KO MEF cells have the advantage of producing no endogenous p62. However,
it is not an osteoclast-like cell. For quantitative study of GFP-LC3 puncta, since there will
be a large number of cells and puncta for counting, a better program or software is
needed to count the puncta using the same criteria for cells over-expresing WT or mutant
p62.
Another challenge is that p62 is also a substrate of autophagy. Therefore it is a little
complicated to explain the regulatory role of p62. There are two possibilities. If mutant
p62 increases autophagic activity, the levels of the mutant p62 will decrease with time,
self limiting the stimulation of autophagy. If mutant p62 decreases autophagic activity,
the levels of the mutant p62 will accumulate through the time. Thus, autophagic activity
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will continue to decrease with time. The second scenario might be the case, so the central
hypothesis of our study would be: PDB-associated p62 mutants impair the autophagic
activity, leading to accumulation of p62, which then further impairs the autophagic
activity. Meanwhile, accumulated p62 mutants further increase the NF-κB signaling and
the formation of osteoclasts, which leads to PDB (Fig. 5.1).

Caution should be exercised when explaining LC3-II data

LC3-II is widely used to estimate autophagy activity [152]. However, we need to
very carefully explain LC3-II data. When autophagic activities increase, LC3-II levels
increase because more autophagosomes form. However, LC3-II itself is degraded by
autophagy, the increased autophagic activity also lead to more degradation of LC3-II,
therefore decreasing the LC3-II levels. Therefore, it is important to measure LC3-II in the
presence and absence of lysosomal protease inhibitors (e.g. E64d and pepstatin A) or
inhibitors which block the fusion of lysosomes and autophagosomes (e.g. NH 4 Cl and
Bafilomycin A1). If mutant p62 really increases the autophagic activity, we will see LC3II levels increases after treatment of either lysosomal protease inhibitors or inhibitors
blocking the formation of autophagolysosome in cells overexpressing mutant p62
compared with cells overexpressing WT p62.
In our study, we used rapamycin as an inducer of autophagy and NH 4 Cl as an
inhibitor. We expected to see LC3-II levels increase upon rapamycin treatment because
more autophagosomes form. However, LC3-II decreased in P2 in the control cells after
rapamycin treatment (Fig. 4.3 A, lane 2 and 6), suggesting that while rapamycin may
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increase the formation of autophagosome, this may ultimately decrease LC3-II levels
through increased degradation. In addition, cells treated with NH 4 Cl generated more
LC3-II (Fig. 4.3 A, lane 9-12), suggesting that NH 4 Cl is a good inhibitor for blocking the
fusion of lysosome and autophagosome. Also, it seems that LC3-II reached maximal
capacity after treatment with NH 4 Cl (Fig. 4.3 A, lane 9-12). In future, it is possible that
using lower NH 4 Cl levels may allow useful measurements of changes in LC3-II levels.

Significance of this study and future directions

In this Chapter, we examined the effect of PDB-associated p62 mutants on
interaction with LC3, GFP-LC3 puncta formation and LC3-II levels upon autophagy
inducer and/or inhibitor treatment. Our data have shown that p62 PDB mutants did not
change interaction with LC3 compared with WT p62. In addition, we speculate that
mutant p62 might impair autophagic activity, leading to the accumulation of p62.
For future studies, in order to better answer whether p62 PDB mutants change
autophagic activity compared with WT p62, methods must be developed to quantify
GFP-LC3 puncta.

Also, for the LC3-II study, other autophagy inducers (Beclin-1,

starvation) and autophagy inhibitors (protease inhibitors E64d and pepstatin A) could be
used. In addition, the question of whether autophagy change the rate of degradation of
p62 PDB mutant compared with WT p62 has not been addressed. In order to address this
question, the half life of p62 could be monitored.
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Figure 4.1. Comparison of the effect of WT p62 or PDB mutant p62 on the
interaction of LC3. (A) HEK293 cells were transfected with FLAG-p62 (WT, A381V,
P392L and M404V) and EGFP-LC3. FLAG-IP was performed, followed by the SDSPAGE. Western blotting was performed using the antibodies against the EGFP and
FLAG. (B) Cell extracts of different samples.

(A)

(B)
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Figure 4.2. Immunostaining of p62 and LC3 in p62 KO MEF cells overexpressing
p62 and GFP-LC3. P62 KO MEF cells were transfected with FLAG-p62 (WT or
M404V) and EGFP-LC3. Twenty-four hours after transfection, cells were fixed with 4%
PFA and permeabilized with 0.1% Triton. Primary antibody FLAG (1:230) and
secondary antibody Hoechst (blue, 1:1000), Alexa Fluor 594 (mouse) (red, 1:300) were
used. Confocal microscopy was applied for observation. Scale bars=20µm. The nuclear
staining of GFP-LC3 is likely due to high levels of overexpression.
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Figure 4.3. Comparison of the effect of WT p62 and p62 PDB mutant on LC3-II
level after rapamycin or rapamycin/NH 4 Cl treatment. (A) Western blotting of LC3-II
in S1, S2 and P2 after fractionation in p62 KO MEF cells overexpressing WT or M404V
p62. P62 KO MEF cells were transfected with FLAG-p62 (WT or M404V). The cells
were treated with rapamycin (200nM) alone for 16 hours or NH 4 Cl (10mM) and
rapamycin (200nM) together for 16 hours. Forty-eight hours post transfection, the cells
were harvested with RIPA buffer. The cell lysates were fractionated into S1, S2 and P2.
The samples were subjected to the SDS-PAGE, followed by Western blotting using the
antibodies against the LC3, FLAG and actin. NT: non-transfection. (B) Quantification of
LC3-II/Actin in S1 treated with rapamycin alone by Image J. The value of WT p62 is
normalized to 100%. Percentage of decrease after rapamycin is shown in red. (C)
Quantification of LC3-II/Actin in S1 treated with rapamycin/NH 4 Cl by Image J. The
value of WT p62 is normalized to 100%. Percentage of increase after rapamycin/NH 4 Cl
is shown in red.

(A)
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(B)

(C)
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Chapter 5. Discussion and future perspective

Significance of this research

In Chapter 2, we introduced a relatively simple proteomic method to identify novel
SUMOylation substrates. Seventy-four SUMOylated proteins were identified by our
proteomic analysis (Table 2.1). Among these proteins, Ran GTPase-activating protein 1
(RanGAP1) [12], proliferating cell nuclear antigen (PCNA) [169] and nucleophosmin
(NPM) [168] have been reported to be SUMOylation substrates. In addition, 61 proteins
have predicted SUMOylation sites and 40 proteins have SUMOylation consensus
sequences (ΨKXE/D) (Table 2.1). Over 50% of these proteins are nuclear proteins (Fig.
2.4), which is consistent with literature that most SUMOylation substrates are in the
nucleus [2]. Altogether, this suggests that our proteomic method is applicable for
identification of SUMOylated substrates.
Moreover, we are the first group to identify a novel SUMOylation substrate
called Drebrin, an actin-binding protein located in the cytosol [3, 45]. We verified
Drebrin SUMOylation by both FLAG and HA immunoprecipitation (Fig. 2.8 A and B).
Furthermore, by using site-directed mutagenesis, we found K185, K186, K270 and K271
might be SUMOylation sites for Drebrin (Fig. 2.9 B). These lysines are conserved among
vertebrate Drebrins by alignment of this region among different species (Fig. 2.7 C),
suggesting that they are functionally important. At last, we observed the protrusion
formation in CHO cells overexpressing Drebrin (WT and mutants) (Fig. 2.10 A), which is
consistent with the literature [53, 54, 57]. However, mutation of these two sites
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(K185R/K186R and K270R/K271R) in Drebrin separately did not appear to change
protrusion formation (Fig. 2.10 B).
Additionally, we also identified several nuclear proteins with multiple predicted
SUMOylation sites (highlighted in Table 2.1), such as general transcription factor II-I,
heterogeneous nuclear ribonucleoproteins C1/C2, nucleolin and 60S ribosomal protein
L24. We could further validate SUMOylation of these proteins by IP and other methods
in the future.
In Chapters 3 and 4, our studies were related to “ubiquitination”, a similar
modification of “SUMOylation”. We focused on an ubiquitin-binding protein, p62. We
studied the effect of PDB-associated p62 mutants on NF-κB signaling and autophagy. In
Chapter 3, we are the first group to use p62 KO MEF cells as a model for studying the
effect of p62 PDB mutant on TNFα-induced NF-κB signaling. Wooten et al. [95] and
Moscat et al. [93] have shown that p62 activated the NF-κB signaling in HEK293 cells
basally. Our study not only showed that p62 activated NF-κB signaling basally (Fig. 3.6
C), but also upon TNFα treatment in p62 KO MEF cells (Fig. 3.9 A) and HEK293 cells
(Fig. 3.10 A). In addition, we also have shown that p62 PDB mutants have a tendency to
increase TNFα-induced NF-κB signaling compared with WT p62 in p62 KO MEF cells
(Fig. 3.9 B and C) and HEK293 cells (Fig. 3.10 B). In addition, our data indicated that
p62 did not increase TNFα-induced NF-κB signaling through increasing TRAF6
polyubiquitination (Fig. 3.14), suggesting other mechanisms may exist (see below).
In Chapter 4, we studied the impact of PDB-associated p62 mutants on autophagy.
We found that PDB mutations did not change the interaction between p62 and the
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autophagy marker protein LC3 (Fig. 4.1 A). Whether p62 PDB mutants change the
autophagic activity is not certain until we optimize our experiments by using autophagy
inducer/inhibitor appropriately.
In summary, my work has expanded our knowledge of the role of PDB-associated
p62 mutants on NF-κB signaling and autophagy, as well as provided insights into several
possible mechanisms, which are shown in an integrated model in Fig. 5.1.

Functional consequences of SUMOylation of Drebrin and other proteins

Although we detected SUMOylation of Drebrin, the modification does not appear
to be involved in protrusion formation in CHO cells (Fig. 2.10 B). So what are the
functional consequences of Drebrin SUMOylation? In Chapter 1, we introduced that
SUMOylation modification of certain protein could bind other proteins only when
SUMOylation is present. For example, only SUMOylated Ran-GAP1 binds RanBP2 [12].
Therefore, we hypothesized that Drebrin SUMOylation might also bind some proteins
only when SUMOylation is present. So how to identify these target proteins which bind
SUMOylated Drebrin, not non-SUMOylated Drebrin? We could take advantage of mass
spectrometry to do the quantification for Drebrin interacting proteins from cells
overexpressing WT Drebrin and mutant Drebrin. We will expect to see the amounts of
some Drebrin interacting proteins are significantly higher in cells overexpressing WT
Drebrin than Drebrin mutants, which impair Drebrin SUMOylation. These proteins are
potential Drebrin interacting proteins only when Drebrin is SUMOylated. We will further
verify their interaction by immunoprecipitation and Western blotting.
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In addition, we could further validate the SUMOylation of proteins with higher
predicted SUMOylation sites, which are highlighted in Table 2.1 by IP and other methods.
We could also study the functional consequences of these proteins in the future.

Mechanisms that PDB-associated p62 mutations increase NF-κB signaling

In Chapter 3, we have shown that PDB-associated p62 mutations (M404V,
A381V and P392L) had a tendency to increase TNFα-induced NF-κB signaling in p62
KO MEF cells (Fig. 3.9) and HEK293 cells (Fig. 3.10). Previously, we hypothesized that
p62 PDB mutant increased TNFα-induced NF-κB signaling through increasing TRAF6
polyubiquitination. However, we showed that TNFα did not increase TRAF6
polyubiquitination in HEK293 cells overexpressing WT and mutant p62 (Fig. 3.14),
which did not support our hypothesis. Therefore, by what other mechanisms do p62 PDB
mutants increase NF-κB signaling?

Several possibilities are described below and

summarized in Fig. 5.1.
(1) TRAFs or RIP polyubiquitination
Moscat et al. [93] showed that p62 could interact with RIP. They also showed that
p62 interacted with TRAF2 in the presence of RIP by immunoprecipitation experiment in
HEK293 cells transfected with p62, RIP and TRAF2 constructs. In their study, they also
showed that upon TNFα treatment, p62 and RIP could be co-immunoprecipitated with
TNF-R1. This suggested that the interaction of p62 and RIP plays a role in the TNFαinduced NF-κB signaling. In Chapter 1, we also introduced that upon TNFα treatment,
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TRAF2 undergoes auto-polyubiquitination (K63-linked), which catalyzes RIP K63linked polyubiquitination and activates the TNFα signaling [93] (Fig. 1.5). Our data
showed that p62 contributed to TNFα-induced NF-κB signaling in p62 KO MEF cells
(Fig. 3.9 A) and HEK293 cells (Fig. 3.10 A) by luciferase assay. Therefore, we
hypothesize that WT p62 increases TNFα-induced NF-κB signaling by increasing
TRAF2 or RIP polyubiquitination. Based on our data that p62 PDB mutants had a
tendency to increase TNFα-induced NF-κB signaling (Fig. 3.9 and 3.10), we also
hypothesize that p62 PDB mutant increases TNFα-induced NF-κB signaling by
increasing TRAF2 or RIP polyubiquitination compared with WT p62.
In order to test our hypothesis, we should first set up a model system in which
TRAF2 or RIP polyubiquitination increases upon TNFα, and the signaling proteins IKK
increase, IκB decreases, phospho-IκB increases after TNFα treatment. Then, we will test
whether TRAF2 or RIP polyubiquitination increases in the presence of p62. If so, we will
have demonstrated that p62 involves in TRAF2 and RIP polyubiquitination. Next, we
will compare the effect of WT p62 and p62 PDB mutant on TRAF2 and RIP
polyubiquitination, see if mutant p62 could further increase polyubiquitination. If these
experiments have results as expected, we could further examine TRAF2 or RIP
polyubiquitination using a variety of different Ub constructs. If we find that TRAF2 or
RIP polyubiquitination is a mixed linkage polyubiquitin chain, not a K63-linked
polyubiquitin chain as we found for TRAF6 (Fig. 3.15), it will be a new finding to the
field, that the mixed linkage polyubiquitin chain could also successfully activate the
signaling.

137

In addition, when the model for studying RANKL-induced NF-κB singnaling is
available in the future, we could test whether PDB-associated p62 mutations increase
RANKL-induced NF-κB signaling through increasing TRAF6 polyubiquitination.
(2) aPKC
In the NF-κB signaling pathway (Fig. 1.5), it is shown that p62 directly interacts
with aPKC through its PB1 domain, and further activates IKK, leading to NF-κB
activation. Therefore, we propose that PDB-associated p62 mutants increase the
interaction with aPKC or increase the activity of aPKC compared with WT p62, and
activate the signaling.
Duran et al. [77] demonstrated RANKL ligand-dependent interactions between p62
and aPKC by immunoprecipitating endogenous p62 in Raw264.7 cells. However, they
did not show negative controls in their IP. In our study, we performed the same
experiment as they did, however our negative control was not working, since HA
antibody could also pull down the endogenous aPKC in the absence and presence of
RANKL (data not shown). Also, the IP efficiency is only about 13%. In the long run, we
could use better IP buffer or better HA antibody to improve the IP efficiency and
diminish the effect of non-specific interaction. We could also use fusion protein p62 or
aPKC (GST, GFP, Myc, FLAG, or DsRed tagged protein) to study the interaction. Once
the experiment is set up, we could introduce WT p62 and p62 PDB mutants, and test if
interactions with aPKC are changed. We could also monitor signaling proteins, such as
IKK, IκB and phospho-IκB, and see if the activity of aPKC increases in the presence of
mutant p62.
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(3) CYLD
Jin et al. [176] reported that a deubiquitinating enzyme, CYLD, negatively
regulates osteoclastogenesis and RANK signaling. They have shown that RANKL
induced a much higher number of ostoclasts from the bone marrow-derived macrophages
(BMDMs) in CYLD knockout mice than control mice. They also showed that
ubiquitinated TRAF6 was accumulated in BMDMs from CYLD knockout mice. In
addition, they showed that CYLD could interact with WT p62, but not UBA-deleted p62
by IP, indicating that the interaction requires the UBA domain. Also, they showed that
the interaction of CYLD and TRAF6 is dependent on p62 and its UBA domain by IP.
In light of their work, we hypothesized that p62 PDB UBA mutant decreases
interaction with CYLD, leading to decreased deubiquitination of polyubiquitinated
TRAF6, further increasing NF-κB signaling. To test this hypothesis, HEK293 cells were
transfected with human HA-CYLD [177] and human FLAG-p62 (WT and mutants) or
mouse p62 (WT and UBA domain deleted). Forty-eight hours after transfection, FLAGp62 IP was performed. In contrast to Jin et al. [176], we found that CYLD coimmunoprecipitated with mouse UBA-deleted p62 (data not shown). In their study, they
used the EGFP-p62, and we used FLAG-p62 in our study. In the future, to rule out nonspecific interactions, we could further change other tags (GST, GFP, Myc and DsRed), or
use the human UBA-deleted p62, not mouse, as a better negative control.
A recent study reported that the de-ubiquitination enzyme CYLD interacted with
wild-type and a non-UBA mutant A381V p62 in osteoclast progenitor cells, but not to the
UBA mutant P392L p62 [178]. Expression of p62 P392L also resulted in increased levels
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of polyubiquitinated TRAF6 and phospho-IκB during osteoclast differentiation. These
findings suggest that at least some p62 PDB mutations might perturb NF-κB signaling by
altering CYLD activity and TRAF6 polyubiquitination.

(4) Other signaling proteins
Our data showed that p62 PDB mutants (M404V, P392L and G411S) suppressed
its association with polyubiquitinated proteins (Fig. 3.11). Layfield et al. [116] also
reported that p62 PDB mutants impaired K48-linked polyubiquitin binding in vitro. In
Chapter 1, we introduced that p62 could bind polyubiquitinated proteins and target them
for degradation by both UPS and autophagy (Fig. 1.6) [8]. Therefore, p62 PDB mutations
may impair their binding with polyubiquitinated proteins that are active signal proteins in
the NF-κB signaling pathway, leading to decreased protein degradation of these proteins,
which might increase the NF-κB signaling. To test this hypothesis in the future, mass
spectrometry could be applied for identification of these important targeting signaling
proteins. In detail, we could use mass spectrometry to do the quantification for the
amount of proteins in cells overexpressing WT p62 and p62 PDB mutant (Fig. 3.11). We
will expect to see that the amounts of some signaling proteins are significantly higher in
cells overexpressing p62 PDB mutant than WT p62. These proteins could be candidate
signaling proteins regulated by p62. When these certain proteins are polyubiquitinated,
p62 PDB mutants fail to bind with these polyubiquitinated proteins, leading to less
capable of sequestering these proteins for degradation. We would confirm these proteins
by IP in cells overexpressing Ub and individual candidate proteins. In addition, p62 PDB
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mutants could also impair autophagy activity leading to accumulation of important
signaling proteins, and further activating NF-κB signaling (see below).

Autophagy in PDB

In a recent autophagy review, it is suggested that autophagy may be related to the
development of bone diseases, although the physiological roles of autophagy in bone are
still mostly unknown [85]. In addition, the presence of inclusion bodies in osteoclasts
seems to link PDB to autophagy [7]. Moreover, it is found that p62 colocalizes with
Autophagy-Linked FYVE-domain containing protein (ALFY) in osteoclasts [7]. While
this suggests that autophagy is linked to PDB [179], little is known about the role of
autophagy in PDB so far. Therefore, the role of autophagy is clearly an area that merits
investigation in the future.
Here, I offer some speculation of the role of autophagy based on the literature and
our preliminary data in Chapter 4. P62 accumulation has been reported in French PDB
patients with and without p62 mutations [175], suggesting that autophagy is impaired in
PDB since p62 is a substrate for autophagy [147]. If impairment of autophagy is
confirmed in a large number of PDB patients, what are the mechanisms?
Defective autophagy in PDB patients could be related to PDB-associated p62
mutants. As described in Chapter 1, p62 mutations are found in about 40% of familiar
PDB [7]. Additionally, p62 is both a substrate and regulator of autophagy [8], therefore
do PDB-associated p62 mutations contribute to the impairment of autophagy in PDB? In
Chapter 4, we tried to use p62 KO MEF cells and several autophagy inducers and/or
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inhibitors to test this hypothesis (Fig. 4.3).

In preliminary experiments with cells

overexpressing WT p62, the LC3-II level decreased less than the control (7.90% vs.
23.20%) after rapamycin treatment (Fig. 4.3 B), suggesting that overexpression of WT
p62 attenuates the autophagic activity. Here, we propose that p62 PDB mutants could
decrease the autophagic activity compared with WT p62, leading to accumulation of p62,
which will further decrease the autophagic activity. In the future, this hypothesis could be
tested by better experiment design, including better software to analyze the GFP-LC3
puncta, more effective and appropriate usage of autophagy inducer and/or inhibitor and
monitoring the endogenous and exogenous p62 levels as indicators of autophagy.
A recent review paper Goode et al. [9] suggests that defective autophagy and
dysregulated NF-κB signaling in PDB may be linked. A number of signaling
intermediaries of the RANKL-induced NF-κB signaling, such as IKK, are targets of
ubiquitination [9, 62], which might be degraded by autophagy. Therefore, it would be
interesting to determine the effect of PDB mutations on p62-mediated autophagic protein
degradation of signaling intermediaries in the NF-κB signaling. In order to address this
question, we could monitor the signaling proteins, including IKK, IκB and phospho-IκB,
in cells treated with autophagy inhibitor/inducer in the absence and presence of RANK or
TNFα.
Considering our findings of p62 PDB mutant on NF-κB signaling, a new
proposed model showing that PDB-associated p62 mutants increase NF-κB signaling by
several of the mechanisms is described in Fig. 5.1. P62 PDB mutants could also impair
autophagy activity leading to accumulation of important signaling proteins, and further
activating NF-κB signaling. Meanwhile, defective autophagy could lead to accumulation
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of mutant p62, which would further impair autophagy and upregulate the NF-κB
signaling, creating a feed-forward pathological cycle. This combined model is presented
in Fig. 5.1.

Other methods and models for studying the PDB

In Chapter 3, we compared cell models for studying the impact of PDB-associated
p62 mutants on NF-κB signaling (Table 3.1). Among them, Raw264.7 cells might be the
best one since they are osteoclast-like cells [170]. The main technique we used is the NFκB luciferase assay.
Aside from Raw264.7 cells and NF-κB luciferase assays, people used other
methods and materials for studying PDB [80, 170]. Additional methods include bone
resorption pit assay [80, 170], in vitro osteoclastogenesis assay [170], osteoclast
apoptosis [80] and others. In addition, besides NF-κB luciferase assays, people used other
methods to examine the NF-κB signaling. These methods include electrophoretic
mobility shift assay (EMSA) [180, 181], nuclear:cytoplasmic ratios of NF-κB [182],
monitoring the rate of IκB degradation [80] and p65 nuclear translocation [183]. In our
study, we monitored the rate of IκB degradation (Fig. 3.3). However, our assay needs to
be optimized by co-tranfection of HA-IκB (or other tags) with the FLAG-p62, in order to
mornitor the IκB in cells expressing FLAG-p62 only. In addition, we also tried p65
nuclear translocation in our study (Fig. 3.4). Again, we need to determine how to quantify
p65 nuclear translocation between cells expressing WT p62 and mutant p62 in the future.
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Mouse models including mice expressing human P392L p62 [184] and P394L
mutant mice [185] were reported previously. Isolated bone marrow macrophages (BMM)
from WT and p62 mutant mice [170], isolated osteoclast precursors from healthy donors
and PDB patients [184], cord blood monocyte (CBM) and peripheral blood mononuclear
cells (PBMC) isolated from blood provided by healthy donors and PDB patients [80]
were also applied in other people’s work.
Compared with our mutant p62 overexpressing in cells, using cells from PDB
patient has its advantage of natural background of the PDB-associated p62 mutants. In
the future, we may learn from these other methods and models.

SUMOylation and NF-κB signaling
In Chapter 2, we mainly focused on identification of novel SUMOylation
substrates. In Chapter 3, we investigated the PDB-associated p62 mutants in NF-κB
signaling, which involves TRAFs polyubiquitination. The linkage of Chapter 2 and
Chapter 3 seems to be that both SUMOylation and ubiquitination are important posttranslational modifications which also share similarities [2].
In addition, several signaling proteins in the NF-κB signaling pathway are reported
to be SUMOylation substrates, such as TNF-R1 [35], IκB [30] and NF-κB essential
modulator (NEMO) [186], the IKK regulatory subunit. Therefore, does SUMOylation
play a role in the NF-κB signaling related to PDB? What is the interplay of SUMOylation
and ubiquitination in the NF-κB signaling related to PDB? Could SUMOylation be
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involved in the mechanisms of PDB? We could expand our knowledge of PDB by
answering these questions.

An integrated model: speculation about the role of PDB-associated p62 mutation

In light of a recent review paper Goode et al. [9], as well as our work and the
literature, I proposed a model integrating the role of PDB-associated p62 mutants on both
NF-κB signaling and autophagy (Fig. 5.1).
PDB-associated p62 mutants increase NF-κB signaling through several
mechanisms including increasing aPKC activity, decreasing CYLD activity, increasing
TRAF6/TRAF2 polyubiquitination, as well as increasing activity of unknown signaling
proteins. Autophagy deficiency was detected in PDB patients, leading to the
accumulation of mutant p62, which is proposed to further impair autophagy (dash line).
P62 accelerates disease progression by upregulating NF-κB signaling through one or
several of the mechanisms. Therefore, PDB-associated p62 mutants play a synergistic
role in disease progression by affecting both NF-κB signaling and autophagy. The
impairment of autophagy in PDB patient results in accumulation of mutant p62, which
accelerates disease progression by increasing the NF-κB signaling. SUMOylation was
found on several NF-κB signaling proteins including IκB [30], TNF-R1[35] and NEMO
[186]. SUMOylation would therefore be involved in other mechanisms of PDB.
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Figure 5.1. A proposed model for the role of PDB mutant p62 in NF-κB signaling
and autophagy. PDB-associated p62 mutants increase NF-κB signaling through several
mechanisms including increasing aPKC activity, decreasing CYLD activity, increasing
TRAF6/TRAF2 polyubiquitination, as well as increasing activity of unknown signaling
proteins. Autophagy deficiency was detected in PDB patients, leading to the
accumulation of mutant p62, which is proposed to further impair autophagy (dash line).
P62 accelerates disease progression by upregulating NF-κB signaling through several
mechanisms. Therefore, PDB-associated p62 mutants play a synergistic role in disease
progression by affecting both NF-κB signaling and autophagy. The impairment of
autophagy in PDB patient results in accumulation of mutant p62, which accelerates
disease progression by increasing the NF-κB signaling. In addition, SUMOylation would
be involved in other mechanisms of PDB.
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APPENDICES
Appendix I: List of all constructs

Plasmid

Insert

Vector

Reference

p3xFLAG-CMV10

N/A

p3xFLAG-CMV10

Sigma

pDsRedM = pDsRed-monomer
C1

N/A

pDsRed-monomer
C1

Clontech

p3xHA-CMV10

N/A

The 3xFLAG tag
of p3xFLAGCMV10 replaced
with 3xHA tag

Chapter 2, made by
Dr. Jozsef Gal

p3xFLAG-SUMO1(FL)

N/A

p3xFLAG-CMV10

Chapter 2

p3xFLAG-CMV10

Chapter 2

p3xFLAG-CMV10

Chapter 2

p3xFLAG-SUMO1(GG-T95R)

p3xFLAG-CMV10

Chapter 2

pDrebrin

pCMV

Chapter 2
Dr. Tomas Brdicka
[165]

p3xFLAG-SUMO1(GG)
p3xFLAG-SUMO1(FL-T95R)

T95R

p3xHA-Drebrin

Human full-length, WT
Drebrin

p3xHA-CMV10

Chapter 2

p3xHA-Drebrin, K185R

Human Drebrin K185R

p3xHA-CMV10

Chapter 2

p3xHA-Drebrin, K186R

Human Drebrin K186R

p3xHA-CMV10

Chapter 2

p3xHA-Drebrin, K192R

Human Drebrin K192R

p3xHA-CMV10

Chapter 2

p3xHA-Drebrin, K270R

Human Drebrin K270R

p3xHA-CMV10

Chapter 2

p3xHA-Drebrin, K271R

Human Drebrin K271R

p3xHA-CMV10

Chapter 2

p3xHA-Drebrin, K185R/K186R

Human Drebrin
K185R/K186R

p3xHA-CMV10

Chapter 2

p3xHA-Drebrin, K270R/K271R

Human Drebrin
K270R/K271R

p3xHA-CMV10

Chapter 2

Contd.
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p3xHA-Drebrin, RRRRR

Human Drebrin
K185R/K186R/K192R/K270
R/K271R

p3xHA-CMV10

Chapter 2

pMYC-p62 (human)

Human full-length, WT p62

pcDNA-MYC

Dr. Marie Wooten

p3xFLAG-p62 (human)

Human full-length, WT p62

p3xFLAG-CMV10

Chapter 3, 4 and 5

p3xFLAG-p62, D335E

Human p62 D335E

p3xFLAG-CMV10

Chapter 3, 4 and 5

p3xFLAG-p62, A381V

Human p62 A381V

p3xFLAG-CMV10

Chapter 3, 4 and 5

p3xFLAG-p62, P392L

Human p62 P392L

p3xFLAG-CMV10

Chapter 3, 4 and 5

p3xFLAG-p62, M404V

Human p62 M404V

p3xFLAG-CMV10

Chapter 3, 4 and 5

p3xFLAG-p62, G411S

Human p62 G411S

p3xFLAG-CMV10

Chapter 3, 4 and 5

pDsRedM-p62

Human full-length, WT p62

pDsRedmonomerC1

Chapter 3, 4 and 5

pDsRedM-p62, A381V

Human p62 A381V

pDsRedmonomerC1

Chapter 3, 4 and 5

pDsRedM-p62, P392L

Human p62 P392L

pDsRedmonomerC1

Chapter 3, 4 and 5

pDsRedM-p62, M404V

Human p62 M404V

pDsRedmonomerC1

Chapter 3, 4 and 5

p3xFLAG- p62 (mouse)

WT, full-length mouse p62

p3xFLAG-CMV10

Chapter 3,made by
Dr. Jozsef Gal [83]

p3xFLAG- p62 (mouse), delta
UBA

Mouse p62, A2-T352

p3xFLAG-CMV10

Chapter 4, made by
Dr. Jozsef Gal [83]

p3xFLAG-TRAF6

Full-length, WT mouse
TRAF6

p3xFLAG-CMV10

Chapter 3 and 4
Made by Dr. Jozsef Gal

NF-κB luciferase reporter

pCMV

Chapter 3 and 4,
Dr. Jiake Xu [170,
173].

GST-rRANKL

pCMV

Chapter 3,
Dr. Jiake Xu [171]

phRL-TK

Promega

p3xHA-Ub

p3xHA

Chapter 3,
Dr. Matthew Gentry
Contd.
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p3xHA-Ub, K48 only

K6R/ K11R/ K27R/ K29R/
K33R/ K63R

p3xHA

Chapter 3,
Dr. Matthew Gentry

p3xHA-Ub, K63 only

K6R/K11R/ K27R/K29R/
K33R/K48R

p3xHA

Chapter 3,
Dr. Matthew Gentry

pcDNA-HA

Chapter 3,
Dr. Marie Wooten

pHA-Ub

pHA-Ub, K29R

K29R

pcDNA-HA

Chapter 3,
Dr. Marie Wooten

pHA-Ub, K48R

K48R

pcDNA-HA

Chapter 3,
Dr. Marie Wooten

pHA-Ub, K63R

K63R

pcDNA-HA

Chapter 3,
Dr. Marie Wooten

pGFP-LC3

Mouse LC3B, P2-V125

pEGFP-C1

Chapter 5,
Made by Dr. Jozsef Gal

HA-CYLD

Human full-length, WT
CYLD

pDEST-HA

Addgene Plasmid
15506 [177].
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Appendix II: List of amplification primers and mutagenic primer sequences.

Number
GJ464

GJ465

GJ468

GJ469

GJ470
GJ471

GJ472

GJ473

GJ474

GJ475

GJ476

GJ477

GJ478

GJ479

Name
T375A reversion
primer in the Wooten
human p62 clone
T375A reversion
primer in the Wooten
human p62 clone
Human p62 upstream
for N-terminal
tagging (EcoRI)
Human p62
downstream, cont.
STOP (KpnI)
Human p62 internal
seq. primer
Human p62 D335E
QuikchangeII primer,
upper strand
Human p62 D335E
QuikchangeII primer,
lower strand
Human p62 A381V
QuikchangeII primer,
upper strand
Human p62 A381V
QuikchangeII primer,
lower strand
Human p62 P392L
QuikchangeII primer,
upper strand
Human p62 P392L
QuikchangeII primer,
lower strand
Human p62 M404V
QuikchangeII primer,
upper strand
Human p62 M404V
QuikchangeII primer,
lower strand
Human p62 G411S
QuikchangeII primer,
upper strand

Primer sequences
5’-CCTTCAGCCCTGTGGGTCCCTCCTG-3’

5’-CAGGAGGGACCCACAGGGCTGAAGG-3’

5’-GCTGGAATTCCGCGTCGCTCACCGTGAAG-3’

5’-CGTCGGTACCTCACAACGGCGGGGGATG-3’

5’-TGGTTGCCTTTTCCAGTGAC-3’
5'-ACTGTTCAGGAGGAGAAGATGACTGGACCCATC-3'

5'-GATGGGTCCAGTCATCTTCTCCTCCTGAACAGT-3'

5'-GGCTGAAGGAAGCCGTCTTGTACCCACATCT-3'

5'-AGATGTGGGTACAAGACGGCTTCCTTCAGCC-3'

5'-CCAGAGGCTGACCTGCGGCTGATTGAG-3'

5'-CTCAATCAGCCGCAGGTCAGCCTCTGG-3'

5'-TCCCAGATGCTGTCCGTGGGCTTCTCTGATG-3'

5'-CATCAGAGAAGCCCACGGACAGCATCTGGGA-3'

5'-TCTCTGATGAAGGCAGCTGGCTCACCAGG-3'

Contd.
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GJ480

GJ757

GJ758

GJ759
GJ760

GJ761

GJ762

GJ763
GJ764

GJ765

GJ769

GJ770

GJ771

GJ772
GJ773

GJ774

GJ775

Human p62 G411S
QuikchangeII primer,
lower strand
hDrebrin Quikchange
Multi, K185R
K186R, upper strand
hDrebrin Quikchange
Multi, K185R
K186R, lower strand
hDrebrin Quikchange
Multi, K192R, upper
hDrebrin Quikchange
Multi, K192R, lower
strand
hDrebrin Quikchange
Multi, K270R
K271R, upper strand
hDrebrin Quikchange
Multi, K270R
K271R, lower strand
hDrebrin internal
sequencing primer
hDrebrin, upstream
primer for p3xHACMV10 (EcoRI)
hDrebrin,
downstream primer
for p3xHA-CMV10
(BamHI)
hDrebrin K185R
Quikchange II, upper
strand
hDrebrin K185R
Quikchange II, lower
strand
hDrebrin K186R
Quikchange II, upper
strand
hDrebrin K186R
Quikchange II, lower
hDrebrin K270R
Quikchange II, upper
strand
hDrebrin K270R
Quikchange II, lower
strand
hDrebrin K271R
Quikchange II, upper
strand

5'-CCTGGTGAGCCAGCTGCCTTCATCAGAGA-3'

5'-GTTCTGGGAGCAGGCCAGGAGGGAAGAAGAGCTGC-3'

5'-GCAGCTCTTCTTCCCTCCTGGCCTGCTCCCAGAAC-3'

5'-AGAAGAGCTGCGGAGGGAGGAGGAGCG-3'
5'-CGCTCCTCCTCCCTCCGCAGCTCTTCT-3'

5'-GAAGAGACCCACATGAGGAGGTCAGAGTCGGAGGTG-3'

5'-CACCTCCGACTCTGACCTCCTCATGTGGGTCTCTTC-3'

5’-AAGACGGATGCAGCTGTGGA-3’
5’-CGTCGAATTCTGCCGGCGTCAGCTTCAG-3’

5’-CGTCGGATCCCTAATCACCACCCTCGAAGC-3’

5'-CTGGGAGCAGGCCAGGAAGGAAGAAGAGC-3'

5'-GCTCTTCTTCCTTCCTGGCCTGCTCCCAG-3'

5'-TGGGAGCAGGCCAAGAGGGAAGAAGAGCTG-3'

5'-CAGCTCTTCTTCCCTCTTGGCCTGCTCCCA-3'
5'-GAAGAGACCCACATGAGGAAGTCAGAGTCGGAG-3'

5'-CTCCGACTCTGACTTCCTCATGTGGGTCTCTTC-3'

5'-GAGACCCACATGAAGAGGTCAGAGTCGGAGGTG-3'

Contd.

151

GJ776

hDrebrin K271R
Quikchange II, lower
strand

5'-CACCTCCGACTCTGACCTCTTCATGTGGGTCTC-3'

152

Appendix III: List of abbreviations

ALS: Amyotrophic lateral sclerosis
aPKC: atypical protein kinase C
CHO: Chinese hamster ovary
Drebrin: Developmentally regulated brain protein
EMSA: Electrophoretic mobility shift assay
ERK: Extracellular responsive kinase
FL: Full-length
GFP: Green fluorescent protein
HA: Hemagglutinin
HEK: Human embryonic kidney
HRP: Horseradish peroxidase
hSUMO-1: human SUMO-1
IKK: IκB kinase
IκB: Inhibitor of NF-κB
KO: Knockout
LC3: Microtubule-associated protein light chain 3
LIR: LC3 interaction region
MEK5: MAPK/ERK kinase 5
MEF: Mouse Fibroblast
NBR1: Neighbor of BRCA1 gene 1
NEMO: NF-κB essential modulator
NF-κB: Nuclear factor κB
NPC: Nuclear pore complex
IP: Immunoprecipitation
PDB: Paget’s disease of bone

153

PB1 domain: Phox and Bem1 domain
PE: Phosphatidylethanolamine
PML: Promyelocytic leukemia
RANK: Receptor Activator of Nuclear Factor κB
Ran-GAP1: Ran-GTPase-activating protein 1
RIP: Receptor-interacting protein
SDS-PAGE: Sodium dodecyl sulfate polyacrylamide gel electrophoresis
SENP: Sentrin/SUMO-specific protease
SUMO: Small Ubiquitin-like Modifier protein
TB domain: TRAF6 binding domain
TBST: Tris-Buffered Saline and Tween 20
TNFα: Tumor Necrosis Factor-alpha
TRADD: TNFR1-associated death domain protein
TRAF6: TNF receptor associated factor 6
TrkA: Tropomyosin-receptor- kinase
UBA domain: Ubiquitin-association domain
UPS: Ubiquitin-proteasom system
WT: Wild-type
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